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Abstract 
 
1. Characterization of the cysteine residues in MG2 
Human salivary mucin MG2 is a 180 kDa glycoprotein secreted by 
submandibular/sublingual and minor salivary glands. Secreted MG2 contains 
a domain with the only two cysteines (Cys45 and Cys50) in the polypeptide 
backbone and it has been shown that this domain in native and recombinant 
MG2 is involved in mucin binding to oral microbes. 
Since reduction and alkylation of MG2 was shown to abolish binding to 
oral microbes, the present study was undertaken to determine whether the 
cysteine residues exist in the dithiol or disulfide form. Electrophoretic 
analyses under reducing and non-reducing conditions showed that 
intermolecular disulfide bonds do not occur between MG2 molecules. The 
same incorporation of radiolabeled iodoacetamide into MG2 was obtained 
with or without prior reduction. When radiolabeled alkylated MG2 was 
digested with Endoproteinase LysC and the derived peptides were separated 
by reversed phase high performance liquid chromatography, radioactivity was 
found in two fractions. Mass spectral analyses of these fractions showed the 
presence of peptide 1 (Cys-Leu-His-Lys-) and peptide 2 (Arg-Cys-Arg-Pro-), 
both containing carboxymethylated cysteines. 
These results show that the cysteines in the structural motif associated 
with bacterial binding exist in the dithiol form and suggest the potential use of 
cysteine-containing peptides as agents to modify interactions of MG2 with 
microbes and oral surfaces.  
 vi 
2.0. Heterotypic complexes of SIgA and MG2 by peptide display 
 
Protein-protein interactions are necessary to maintain homeostasis and to 
integrate different biological systems. Heterotypic complexes between SIgA and 
MG2 in saliva have been suggested to possibly promote microbial clearance 
from the oral cavity preventing colonization by potential pathogens. 
Random peptide display library was used to investigate whether 
previously unrecognized heterotypic complexes involving SigA, MG2 and other 
salivary or microbial proteins. Panning the random peptide display library with the 
anti-IL8 antibody (positive control) showed that this procedure reliably selected 
clones containing the IL8 epitope. SIgA and MG2 were panned with the random 
library for twelve days. Sequence analysis of selected SigA clones identified a 
motif consisting of short tetra- or pentapeptides present in microbial proteins that 
have the potential to interact with SIgA in vivo. These interactions suggest 
several possible mechanisms by which SIgA could prevent or minimize the 
adverse effects of stemming from microbial damage to human health. Sequence 
analyzes of selected MG2 clones identified dodecapeptides containing the 
consensus sequence, Ala-Leu-Leu-, which occurs in salivary lactoferrin. Far 
Western blotting experiments confirmed that MG2 and lactoferrin form a 
heterotypic complex in vitro. Lactoferrin is an iron-binding protein that, similar to 
MG2, exhibits antimicrobial properties. Formation of a heterotypic complex 
between these salivary proteins in vivo may localize these antibacterial and anti-
inflammatory molecules in specific sites in the oral cavity, improve their 
 vii 
resistance to proteolytic attack and prolong their transit time in the oral 
environment.  
To date this is the first study to use peptide display technology with 
salivary proteins and to identify a heterotypic complex between MG2 and 
lactoferrin. Complexing between salivary and non-salivary proteins in the oral 
cavity may prove to be an important factor in the maintenance of oral health.  
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 1 
Introduction 
 
 
1. Saliva 
Saliva is a fluid that maintains oral health and protects hard and soft 
tissues in the oral cavity from mechanical, thermal and chemical irritation 
(Sreebny, 2000). Whole saliva contains the secretions of both the major and 
minor salivary glands, fluid derived from the gingival crevice, oral epithelial cells, 
bacteria, bacterial products and food debris. The composition of the major 
constituents found in whole saliva is given in Table 1. The origin, secretion, flow 
rate, functions and components of this important fluid will be discussed in detail 
in subsequent sections. 
 
1.1. Salivary glands 
The three pairs of major salivary glands are the parotid, submandibular 
and sublingual. Parotid glands are the largest and produce a predominantly 
serous secretion. Under unstimulated conditions, they contribute 22-30% of the 
whole saliva volume and upon stimulation the contribution increases to  40-50%. 
Submandibular glands produce a mixture of serous and mucous secretion and 
sublingual glands produce mainly a mucous secretion. Under unstimulated 
conditions these two pairs of glands contribute 62-70% of the volume of whole 
saliva and upon stimulation their contribution decreases to 42-52% (Dawes, 
1996).  
The minor salivary glands are usually localized in the submucosa 
surrounded by connective tissue or between muscle fibers of the labial, buccal,  
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Table 1. Partial list of whole saliva components 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inorganic components  
                            
Calcium                                                 
Magnesium                                            
Sodium                                                  
Potassium                                             
Phosphate                                             
Chloride                                                 
Bicarbonate                                            
 
Organic components                                                                                  
 
Urea (adults)                                           
Urea (children)                                        
Uric acid                                                  
Amino acids (free)                                   
Glucose (free)                                         
Lactate                                                    
Fatty acids (mg/l)                                    
 
Macromolecules                                        
 
Proteins                                                    
Glycoproteins                                           
Amylase                                                   
Lysozyme                                                 
Peroxidase                                               
SIgA                                                         
Lipid                                                          
  (mM) 
 
1.0 - 2.0 
0.2 - 0.5 
6.0 - 26.0 
14.0 - 32.0 
2.0 - 23.0 
17.0 - 19.0 
2.0 - 30.0 
 
(mM)
 
2.0 - 6.0 
1.0 - 2.0 
0.2
1.0 - 2.0 
0.05
0.1
10.0
 
(mg%) 
 
140 - 200 
11 - 30 
38.0
10.9
0.3
19.4
2- 3 
          Adapted from Whelton, 1996.  
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lingual and palatine areas (Hand et al., 1999). Their total number in the oral 
cavity has been estimated to be approximately 600 (Provenza, 1964). The 
product of minor salivary glands is predominantly mucous in character and they 
contribute 7-8% of the volume of whole saliva under both stimulated and 
unstimulated conditions (Dawes, 1996).                                                                                                              
 
1.2. Salivary secretion 
In saliva, the secretion of proteins is stimulated by release of 
noradrenaline from sympathetic nerves and fluid secretion is stimulated by the 
release of acetylcholine from parasympathetic nerves. Although these processes 
are stimulated by different nerves, the separation breaks down at the second 
messenger level. Interactions between Ca2+ and cAMP in intracellular signaling 
pathways integrate protein and fluid secretion to produce the saliva (Smith, 
1996).  
 
1.3. Salivary flow rates 
In an awake period of 16 hours, with an unstimulated flow rate of 0.3 
ml/min, a volume of approximately 300 ml of saliva will be produced. Sleeping 7 
hours, with flow rates that drop to less than 0.1 ml/min, a volume of 
approximately 40 ml of saliva will be produced. Spending approximately 1 hour 
eating per day, with flow rates of 4 ml/min, 240 ml of saliva will be produced. 
Therefore, the sum of these processes results in the production of approximately 
600 ml of saliva per day (Dawes, 1996). 
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In healthy individuals, unstimulated salivary flow rates have a large range 
(low, 0.1-0.25 ml/min and normal, 0.25-0.35 ml/min). Different factors affect the 
flow rates in different subjects. The degree of hydration is important since a 
reduction of the body water content by 8% will virtually stop the salivary flow. The 
influence of the circadian rhythm can be observed when flow rates from the end 
of the afternoon (highest) and during sleep (lowest) are compared. A vast 
number of classes of drugs also affect the salivary flow rate as a side effect (i.e., 
analgesics; antinauseants; antidepressants; antihistamines; antihypertensives; 
anxiolytics; diuretics; muscle relaxants; sedatives; and others).  
Since studies conducted to determine the average stimulated flow rate in 
humans have used different types of stimuli (grape candy, lemon juice, 1% citric 
acid), comparison of the obtained values (low, 0.7-1.0 ml/min and normal, 1.0-3.0 
ml/min) is difficult. The duration of stimulation has been shown to not affect the 
total protein concentration in parotid and submandibular/sublingual glandular 
secretion. Upon stimulation the pH and the concentration of sodium, bicarbonate 
and chloride were reported to increase, while levels of magnesium and 
phosphate decreased (Dawes, 1987; Watanabe and Dawes, 1988).  
 
1.4. Xerostomia  
The subjective feeling of oral dryness is known as xerostomia. Diagnosis 
is largely related to individual symptoms. Studies showed that a large number 
(13-21%) of young people (18-30 years), complained of oral dryness and this 
number was increased (30-40%) among subjects older than 60 years (Sreebny, 
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2000). The higher frequency of xerostomia observed among older subjects can 
be explained, at least in part, by the increase in use of prescription medications 
and a replacement of 20-40% of functional parenchymal cells in parotid and 
submandibular gland by fat and connective tissue (Waterhouse et al., 1973; Scott 
et al., 1987). 
In therapeutic irradiation of the head and neck region, and in Sjogren’s 
Syndrome, the significant reduction in the salivary flow is associated with 
development of rampant caries, mucositis, dysphagia, frequent infections, 
difficulty in eating, weight loss and depression (al-Hashimi, 2001). Isolated or 
combined, these impairments lead to a severe decrease in the life quality of 
patients. Hopefully in the next 20 years, surgical procedures utilizing gene 
transfer should be available, and improve repair in salivary glands damaged by 
radiation and other conditions (Baum et al., 2000). 
 
1.5. Salivary functions 
Saliva is an important ion reservoir since it is supersaturated in calcium 
and phosphate salts with respect to hydroxyapatite. As a result saliva will 
continuously participate in the remineralisation of the enamel. 
The salivary buffering capacity is primarily derived from bicarbonate and to 
a minor extent from phosphate. Under high flow rates, the bicarbonate 
concentration increases to approximately 60 mM and this neutralizes plaque 
acidity, preventing the progression of early caries lesions (Higham and Edgar, 
1989; 1989; Mandel, 1989). 
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Salivary fluid assists speech and in the formation and swallowing of food 
bolus. The rapid removal of carbohydrates, microorganisms and their derived 
products from the oral cavity, salivary clearance, is beneficial to prevent caries 
although the reverse is true for protective substances such as fluoride, 
chlorhexidine and anti-microbial proteins. 
Saliva exists as a film of 0.1mm or less in thickness that under 
unstimulated conditions, is estimated to move at different rates (0.8 – 8.0 
mm/min) in different areas of the oral cavity (Dawes et al., 1989; Dawes and 
Macpherson, 1993). Physical forces (ionic, hydrophobic, hydrogen bonding, and 
van der Waals) selectively adsorb salivary components to the enamel surfaces 
forming the acquired enamel pellicle. Upon binding, some receptors on salivary 
molecules are exposed to bacteria, facilitating colonization of the tooth surface, 
and resulting in the formation of the dental plaque biofilm (Marsh and Bradshaw, 
1995). 
Interactions of salivary components with different microorganisms in the 
oral cavity and the formation of heterotypic complexes between salivary proteins 
will be discussed in the next two sections.  
 
1.6. Saliva and microorganisms 
Salivary proteins mediate microbial colonization in the oral environment by 
multiple mechanisms. Binding of microbes to salivary components facilitates 
microbial clearance. Proteins that occur in saliva and are encountered in the 
acquired enamel pellicle serve as receptors for microbial attachment. Several 
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salivary proteins exhibit anti-microbial properties and therefore, can inhibit and 
kill oral microbes. Salivary components also serve as an energy source for 
microbes, favoring some species of microorganisms that contain the necessary 
apparatus to metabolize these proteins (Scannapieco, 1994). Salivary proteins 
have been reported to interact with several different species of bacteria (i.e., 
Streptococcus mutans; Streptococcus sanguis; Streptococcus gordonii; 
Actinomyces viscosus; Actinobacillus actinomycetemcomitans; Pseudomonas 
aeruginosa; and others), viruses (i.e., herpes simplex virus and HIV type 1) and 
with the pathogenic yeast, Candida albicans (Scannapieco, 1994; Marcotte and 
Lavoie, 1998).   
 
1.7. Saliva and heterotypic complexes 
Studies with purified salivary proteins have shown that interactions can 
occur between different molecules in saliva (Levine, 1993). The formation of 
protein complexes usually involves ionic forces, hydrogen bonding, and/or 
hydrophobic interactions. It seems likely that such complexes modulate the 
functions of these molecules in vivo. 
Secretory IgA and parotid agglutinin appear to interact in a calcium-
dependent association and this complex may enhance their activity (Rundegren 
and Arnold, 1987). The antimicrobial effect of lactoperoxidase on S. mutans was 
increased when complexed with SIgA (Tenovuo et al., 1982). Complexes 
between MG2 and SIgA in saliva have also been described (Biesbrock et al., 
1991). MG1 selectively formes heterotypic complexes with amylase, proline-rich 
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proteins, statherin, and histatins (Iontcheva et al., 1997) and binding of statherin 
and histatins to non-glycosylated portions of the MG1 protein core was observed 
in a study that used the yeast two-hybrid system to map the interacting domains 
of MG1 (Iontcheva et al., 2000). 
Among other advantages in the formation of heterotypic complexes in 
saliva, it can be mentioned that complexing may enhance the anti-microbial 
properties of proteins participating in these interactions, decrease protein 
susceptibility to bacterial enzymes and localize salivary proteins in specific areas 
of the oral cavity. 
 
2. Salivary proteins 
Salivary proteins are synthesized in serous and mucous acinar cells, 
ductal cells, and also in cells of the immune system that migrate to the salivary 
glands. The major salivary protein families show a diverse molecular weight 
range, starting at 3 kDa (histatin-5) and going up to 40 million Daltons (multimeric 
MG1). Some salivary protein families display specific functions, but functional 
overlap also occurs, and can be considered as an advantage since in the 
absence of one component, an increase in the production of a second one could 
theoretically fulfill the necessary requirements ascribed to the one missing. This 
process can be observed in patients who are SIgA deficient and as a 
compensatory mechanism, exhibit higher levels of components from the innate 
system, as well as of IgG (Gleeson et al., 1995). The major salivary protein 
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families, their characteristics and functions will be briefly discussed in the 
subsequent sections. 
 
2.1. Amylase  
α-Amylases belong to a family of proteins containing different isoforms 
that can be distinguished by their carbohydrate (CHO) content. This salivary 
protein is abundant in parotid (100 mg%) and submandibular (25 mg%) 
secretions and occurs with an apparent molecular weight of 56 kDa (low CHO 
content) or 62 kDa (higher CHO content). Amylase is a calcium-containing 
metalloenzyme which hydrolyses α-1,4 bonds of starch (i.e., amylose; 
amylopectin) to generate maltose, the major end-product, and also glucose 
(Scannapieco et al., 1993). It has also been reported that amylase binds to S. 
gordonii and Streptococcus mitis in vitro. This salivary protein was found in the 
acquired enamel pellicle, suggesting that it could modulate bacterial colonization 
(Kilian et al., 1990; Li et al., 2002). Interactions between amylase and oral 
bacteria could be beneficial if they promote bacterial clearance but they could 
also be undesirable if amylase-derived sugars provide substrates for bacterial 
fermentation and acid production leading to demineralization of enamel and the 
development of caries. 
 
2.2. Cystatins 
Cystatins are cysteine-protease inhibitors that occur in body fluids. In 
saliva, cystatins are present in submandibular and sublingual secretions and 
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have an apparent molecular weight of 12.5-13.5 kDa. They inhibit selected 
bacterial proteases and also proteases generated from leukocyte lysis in 
diseased periodontal tissue (Aguirre et al., 1992). Cystatins also inhibit crystal 
growth and have been reported to be a component of the acquired enamel 
pellicle (Bradway et al., 1992). 
 
2.3. Histatins 
This family of small, cationic, histidine-rich peptides contains twelve 
members. Histatin 1 and 3 are encoded in distinct genes and are secreted intact 
while histatins 2, and 4-12 are derived from proteolytic cleavage of histatins 1 
and 3 during secretion (Troxler et al., 1990). They inhibit crystal growth and 
exhibit affinity for hydroxyapatite, however, the anti-fungal activity is probably the 
most important property of histatins. They possess fungicidal and fungistatic 
properties against several species of Candida.  (Nikawa et al., 2001; Lamkin and 
Oppenheim, 1993). Antibacterial properties and binding to zinc and cooper are 
also properties ascribed to histatins (Lamkin and Oppenheim, 1993; Grogan et 
al., 2001).  
 
2.4. Lactoferrin 
Salivary lactoferrin is a single chain iron-binding glycoprotein with an 
apparent molecular weight of 80 kDa that is closely related to transferrin, a 
plasma iron-transport protein. Lactoferrin has a concentration of approximately 1 
mg% in the secretions derived from the major salivary glands, and is folded in 
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two lobes that can each reversibly bind one ferric ion along with a synergistic 
anion (Brock, 2002). Lactoferrin posses antibacterial, antimycotic, antiviral, 
antineoplastic and anti-inflammatory activity (Weinberg, 2001) and therefore is an 
active component of innate immunity in the oral cavity. The ability of this salivary 
protein to remove free iron in fluids, decreasing the availability of the metal to 
microbes, is well recognized (Mukherjee et al., 1997). The basic N-terminal 
region of lactoferrin has been described to penetrate bacterial cell membranes 
and to exhibit antibacterial properties (Yamauchi et al., 1993). The basic 
character (pI 8-9) of lactoferrin allows binding to many acidic molecules that 
occur on cell surfaces.  Due to all the properties ascribed to lactoferrin, the 
development and use of a recombinant human form of lactoferrin should be of 
interest to be used in a wide range of medical conditions (Weinberg, 2001). 
 
2.5. Lysozyme 
This salivary protein has a molecular weight of 13.9 kDa and is composed 
of 147 amino acid residues including the signal peptide. It is present in the 
secretions of parotid and submandibular glands and it is one of the components 
of the antibacterial system that exits in saliva. Lysozyme is known to hydrolyze 
specific bonds (β-1-4 bonds between N-acetylglucosamine and N-
acetylmuraminic acid) that occur in cell walls of gram-positive bacteria, promoting 
cell lysis and death (Tenovuo, 1989; 2002). Lysozyme has also been reported to 
kill and/or interfere with the metabolism of C. albicans (Wu et al., 1999). 
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2.6. Peroxidase 
In saliva, peroxidase is produced and secreted by the major salivary 
glands and oral polymorphonuclear leucocytes release myeloperoxidase into the 
gingival crevicular fluid in amounts that are proportional to the extent of gingival 
inflammation (Cao and Smith, 1989). Both enzymes can catalyze the oxidation of 
thiocyanate ion (SCN-) using hydrogen peroxide (H2O2) to produce 
hypothiocyanite ion (OSCN-) or hypothiocyanous acid (HOSCN).  
Hypothiocyanite and hypothiocyanous acid exhibit bacteriostatic activity and they 
have been reported to oxidize intracellular sulfhydryl groups, damage cell 
membranes, inhibit glycolysis and glucose uptake and also acid production in 
bacterial cells (Lenander-Lumikari et al., 1992). Both purified human salivary 
peroxidase and myeloperoxidase have shown anti-streptococcal bacterial 
inhibition suggesting that the peroxidase system should also modulate the growth 
of oral Streptococci in vivo (Lumikari et al., 1991). Lysozyme and peroxidase at 
physiological concentrations were reported to have a synergistic effect that 
results in inhibition of glucose metabolism by S. mutans (Lenander-Lumikari et 
al., 1992).  
 
2.7. Proline-rich proteins (PRPs)  
This salivary protein family is comprised of acidic and basic 
phosphoproteins and basic glycoproteins that have an amino acid content of 75-
80% proline, glutamine, and glycine. The molecular weight of the majority of the 
PRPs ranges from 9 to 39 kDa and derives from differential RNA splicing and 
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posttranslational modifications of gene products (Scannapieco, 1994). They 
exhibit genetic polymorphism and are major components of the salivary 
secretions. 
Several functions have been attributed to PRPs. The first 30 residues of 
the N-terminal region of this molecule bind calcium, helping to maintain saliva in 
a state of supersaturation with respect to calcium phosphate salts and inhibiting 
crystal growth (Bennick, 1982). They exhibit high affinity for hydroxyapatite and 
are components of the acquired enamel pellicle (Bennick et al., 1983). In solution 
phase PRPs do not bind to bacterial surfaces, although, upon binding to host 
surfaces, PRPs have been proposed to undergo a conformational change that 
will expose previously inaccessible domains (cryptitopes) that can serve as 
bacterial receptors (Gibbons, 1989). PRPs have been reported to mediate 
adhesion of different species of bacteria (i.e., A. viscosus; S. mutans; S. gordonii) 
to the tooth surface and therefore, modulate the oral microflora (Scannapieco, 
1994). 
  
2.8. Statherins 
This salivary peptide has a molecular weight of 5.38 kDa and is composed 
of 43 amino acid residues. This acidic and carbohydrate-free tyrosine-rich 
phosphoprotein is present in the secretions from parotid and submandibular 
glands. Statherin inhibits crystal growth and binds with high affinity to 
hydroxyapatite surfaces (Scannapieco, 1994; Schupbach et al., 2001). These 
two functions have been reported to be derived from residues in the N-terminal 
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region of this molecule (Douglas et al., 1991).  Like PRPs, upon binding to the 
hydroxyapatite surface, statherin may also undergo a conformational change, 
exposing hidden receptors that will be available to interact with oral 
microorganisms (Gibbons et al., 1991). This protein has been reported to bind to 
Porphyromonas gingivalis (Amano et al., 1994), A. viscosus (Gibbons et al, 
1988), Actinomyces naeslundii (Stromberg et al., 1992) and Fusobacterium 
nucleatum (Xie et al., 1991). 
 
2.9. Secretory IgA  
SIgA is the predominant immunoglobulin isotype found in saliva and 
represents the adaptive immune system in the oral cavity (Marcote and Lavoie, 
1998). This immunoglobulin is produced by plasma cells that migrate to the 
vicinity of acini and ducts in salivary glands and are produced as a host response 
to antigenic stimulus (McNabb et al, 1981; Michalet et al., 1977). 
SIgA exists as a polymeric molecule comprised of two (alpha) heavy and 
two (kappa or lambda) light chains linked together by disulfide bonds, a secretory 
component and a J chain. The J chain links two IgA molecules forming a dimer 
and the secretory component, a heavily glycosylated protein, stabilizes and 
reduces the susceptibility of SIgA to bacterial proteases (Scannapieco, 1994). A 
schematic representation of a SIgA molecule is shown in Figure 1. 
After secretion from plasma cells, dimeric IgA binds to the 
polyimmunoglobulin receptor on the basolateral face of epithelial cells. The 
complex undergoes transcytosis and is transported in a vesicle to the apical  
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Figure 1. Schematic representation of a SIgA molecule.  
One molecule of SIgA is composed of two IgA monomers (150 kDa each) linked 
by a J (joining) chain (15.6 kDa) and a secretory component (SC; 70 kDa). Both 
the J chain and the SC are disulfide linked to the fragment crystallizable region 
(Fc). Each IgA monomer consists of two α-heavy chains (50 kDa each) and two 
κ-light chains (25 kDa each) linked by disulfide bonds. The specific antigen-
binding site is localized in the Fab region.  
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surface of the epithelial cells. The polyimmunoglobulin receptor is partially 
cleaved, and the remaining part linked to the IgA dimer becomes the secretory 
component. 
Two IgA subclasses, IgA1 and IgA2, occur in humans. The difference is in 
the amino acid composition of the heavy chains and IgA2 is reported to be more 
resistant to bacterial proteases that usually can cleave IgA1 on the hinge region 
(Kerr, 1990).  
 
2.9.1. SIgA response 
Oral antigens induce salivary IgA production by two possible mechanisms 
that can occur simultaneously, enhancing the response of the adaptive immune 
system in the oral cavity. Minor salivary glands have short ducts and are 
continuously exposed to oral antigens by natural retrograde flow (Nair, et al., 
1983). A study reported that macrophages will bind to these antigens and 
present them to immune cells present in the area surrounding the salivary glands 
suggesting that a functional salivary-gland immune-response pathway exists and 
can function independently of a gut-associated lymphocyte-homing mechanism 
(Pappo et al., 1988). The second mechanism involves oral antigens that are 
swallowed, transported from the intestinal lumen by accessory cells and 
presented to precursors IgA B cells and to T cells localized in the gut-associated 
lymphoid tissues (GALT). Following antigen presentation, these cells will 
proliferate and leave the GALT, migrating to the lamina propria of the salivary 
glands where they will be selectively retained and initiate the SIgA antigenic 
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specific response (Marcotte and Lavoie, 1998).   
 
2.9.2. SIgA cell mediated functions  
Polymorphonuclear neutrophils (PMNs), monocytes, macrophages, 
eosinophils and lymphocytes express receptors for the Fc portion of IgA. There 
have been reports suggesting that IgA induces phagocytosis and respiratory 
burst (measured by the released of H2O2) in monocytes, macrophages and 
PMNs (Marcotte and Lavoie, 1998). However, it has been also reported that IgA 
inhibits phagocytosis by PMNs (Saito et al., 1991), the generation of respiratory 
burst and also down regulates the inflammatory response in activated monocytes 
(Wolf et al., 1994). Nevertheless, the small number of leukocytes and vast 
number of microbes in secretions suggests that the IgA-dependent cell mediated 
response should not be a major mechanism of defense on mucosal surfaces. 
 
2.9.3. SIgA and complement activation  
IgA does not activate the classical complement pathway (Russell and 
Mansa, 1989) and the ability to activate the alternative pathway is controversial. 
There are reports that complement activation by IgA consumes the C3 
component but rarely the C5 component, a major anaphylatoxic and 
inflammatory peptide (Kerr, 2000). IgA has been reported to decrease the 
complement-mediated activity of IgG and IgM, suggesting that competition 
between these immunoglobulin isotypes for antigen binding sites or for initial 
components of the classical pathway should occur (Marcotte and Lavoie, 1998). 
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In view that complement components are not abundant in secretions, the limited 
or absent IgA mediated complement activity at mucosal surfaces should not 
affect microbial killing in the oral cavity.   
 
2.9.4. Interactions between SIgA and microorganisms  
The inhibition of bacterial adherence to host surfaces is an important 
property of SIgA. Adherence of oral Streptococci and C. albicans to buccal 
ephitelial cells has been reported to be inhibited by human SIgA (Williams and 
Gibbons, 1972; Vudhichamnong et al., 1982). On tooth surfaces, different results 
were obtained since SIgA has been reported to both inhibit (Hajishengallis et al., 
1992) and to promote (Kilian et al., 1981) the adhesion oral Streptococci. The 
carbohydrate content of SIgA confers hydrophilic properties to these molecules 
and upon binding to adhesins present on bacterial surfaces, SIgA reduces their 
negative surface charge and hydrophobicity, limiting possible ionic and 
hydrophobic interactions between bacteria and host receptors. SIgA inhibits 
bacterial enzymes by blocking their binding to substrates or by interfering with 
the enzyme-substrate complex (Marcotte and Lavoie, 1994). Interactions 
between SIgA and HIV play an important role in the immune system (Skott et al., 
1999; Moja et al., 2000; Devito et al., 2000) and were reported to possibly 
prevent HIV-1 infection (Matsuda and Noda, 2000). SIgA antibodies to 
hemagglutinin of the inluenza virus reduce viral attachment and penetration into 
cells (Taylor and Dimmock, 1985). Some studies have reported that in infected 
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epithelial cells expressing the polymeric Ig receptor, IgA mediates virus 
neutralization (Mazanec et al., 1992). 
 
2.9.5. SIgA synergism and heterotypic complexes with other salivary 
proteins 
SIgA may enhance the antimicrobial properties of lactoferrin by blocking 
the production of bacterial siderophores that can remove iron from lactoferrin 
(Funakoshi et al., 1982; Moore et al., 1984). The occurrence of heterotypic 
complexes involving these two salivary proteins in secretions, has also been 
reported (Kilian et al., 1988). A synergistic action between mucins and SIgA may 
promote bacterial clearance (Magnusson and Stjernstrom, 1982) and the 
formation of a heterotypic complex between MG2 and SIgA may facilitate the 
removal of P. aeruginosa and Staphylococcus aureus from the oral environment 
(Biesbrock, 1991). Complexing between SIgA and salivary agglutinins should 
enhance bacterial aggregation (Rundegren and Arnold, 1989). Therefore, SIgA 
has been reported to form heterotypic complexes with three different salivary 
proteins. 
 
2.10. Mucin glycoprotein-1 
Originally, salivary mucin MG1 was thought be the product of the MUC5B 
gene (Troxler et al., 1995; Desseyn et al., 1997; Keates et al., 1997). However a 
recent study reported that two cDNA clones containing MUC4 tandem repeats 
were isolated from a human submandibular gland cDNA library, and also that 
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recombinant MUC4 produced in a bacterial expression system cross-reacted with 
an antibody directed against deglycosylated MG1. This shows that human 
salivary mucin MG1 contains both MUC5B and MUC4 gene products (Liu et al., 
1998). Studies using capture ELISAs determined that the mean concentration of 
MG1 in whole saliva to be approximately 23.3 mg% (Rayment et al., 2000). 
  
2.10.1. MG1 expression 
Different studies, using immunochemical assays failed to identify the 
expression of MG1 in the parotid gland (Cohen et al., 1990; Nielsen et al., 1996). 
In contrast, the same studies have identified that mucous acinar cells in 
submandibular, sublingual, labial and palatal glands express this salivary mucin.  
 
2.10.2. MG1 characteristics 
High molecular weight salivary mucin MG1 is an oligomeric protein with an 
apparent molecular weight of 20-40 million Daltons composed of disulfide-linked 
subunits (1 million Dalton each). MG1 is comprised of 15% protein, 78% 
carbohydrate, 7% sulfate and less than 0.06% of covalently bound fatty acids 
(Loomis et al., 1987). The polypeptide backbone is enriched with respect to 
serine, threonine, proline and alanine (43% combined). The O-linked 
oligosaccharide side chains (4 to 16 residues in length) constitute the majority of 
the carbohydrate content and are mainly composed of N-acetylglucosamine, N-
acetylgalactosamine, galactose, fucose and sialic acid corresponding to 29%, 
9.4%, 24.2%, 10.5% and 4% of the total mucin dry weight, respectively. N-linked 
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oligosaccharides are also present in this mucin. MG1 has a density of 1.4-1.5 
g/ml that is derived from the high sugar content (Troxler et al., 1995). Studies 
using 1-anilino-8-naphthalenesulfonate (ANS) and N-phenyl-1-naphthylamine 
(NPNA) showed that MG1 contains hydrophobic domains localized on the 
polypeptide backbone of this molecule (Loomis et al., 1987). The occurrence of 
blood group antigens ABH, Lea and Leb on MG1 has also been reported 
(Prakobphol et al., 1993). 
 
2.10.3. MG1 functions 
The high content of carbohydrates renders MG1 resistant to proteolytic 
attack (Wu et al., 1994). The abundance of charged groups of sialic acid and 
sulfate attached to the apoprotein gives a hydrophilic nature to MG1, enhances 
hydration and prevents desiccation of the oral mucosa. The viscoelastic 
character of this salivary protein reduces the impact of mechanical forces on oral 
surfaces, facilitates the slide and glide movements, and aids in mastication, 
speech and swallowing (Prinz and Lucas, 1997).  
MG1 binds to hydroxyapatite and partial deglycosylation of this molecule 
did not reduce binding, suggesting that the protein core of nonglycosylated 
domains is involved in those interactions (Tabak et al., 1985; Amerongen et al., 
1989). It is interesting to note that salivary pellicles can reduce the 
demineralisation of enamel surfaces in vitro, and that pellicles formed with saliva 
depleted of mucins provided significantly less protection to demineralization 
(Tabak and Bowen, 1989). Furthermore, pellicles formed with parotid secretion, 
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where both salivary mucins MG1 and MG2 are known to be absent, did not 
protect the enamel surface against demineralization (Amerongen et al., 
1987,1988). Since MG1 was detected in an in vivo 2 hour acquired enamel 
pellicle, this mucin should be important to maintain the integrity of the enamel 
surfaces (al-Hashimi and Levine, 1989). 
MG1 interacts with oral microbes and has been shown to bind to P. 
gingivalis (Amano et al., 1994), Haemophilus parainfluenzae (Veerman et al., 
1995), P. aeruginosa (Reddy, 1996) and Helicobacter pylori (Veerman et al., 
1997). Binding to HIV-1 and to the yeast C. albicans has also been reported 
(Bergey et al., 1994; Edgerton et al., 1993). 
This mucin has been shown to form heterotypic complexes with amylase, 
proline-rich proteins, statherin, and histatins (Iontcheva et al., 1997) and 
molecular mapping studies by the yeast two-hybrid system have identified 
statherin- and histatin-binding domains in MG1 (Iontcheva et al, 2000). Together, 
the interactions with oral microbes and with different salivary proteins indicate 
that salivary mucin MG1 is an active component of the innate immune system. 
 
2.11. Mucin glycoprotein-2 
MG2 is a salivary mucin encoded in the MUC7 gene located on 
chromosome 4q13-q21 (Bobek et al., 1993; 1996). It is a unique member of the 
mucin gene family because it is a small, soluble and monomeric molecule 
(Moniaux et al., 2001). The presence of several helix-breaking proline residues in 
the protein core maintains this molecule in an extended spatial configuration 
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resembling a bottle-brush (Loomis et al., 1987). Studies using capture ELISAs 
determined the mean concentration of MG2 in whole saliva to be approximately 
13.3 mg% (Rayment et al., 2000). 
 
2.11.1. MG2 expression 
There is controversy with respect to which salivary gland cell type 
expresses MG2, although the absence of this salivary mucin in parotid glands 
appears to be a consensus in the literature (Cohen et al., 1991; Khan et al., 
1998; Nielsen et al., 1996). Immunochemical and in situ hybridization 
experiments have localized MG2 in a subset of mucous acini in submandibular 
and labial salivary glands (Cohen et al., 1991; Khan et al., 1998). In contrast, 
another immunochemical study has localized the MG2 expression to serous acini 
of submandibular, sublingual, labial and palatal salivary glands (Nielsen et al., 
1996). Nevertheless, the studies above detected MG2 expression in acinar cells 
of submandibular, sublingual and some minor salivary glands.   
 
2.11.2. MG2 characteristics 
MG2 has an apparent molecular weight of approximately 180 kDa and is 
composed of 30.4% protein, 68% carbohydrate and 1.6% sulfate (Loomis et al., 
1987). A schematic representation of a molecule of MG2 is shown in Figure 2. 
The polypeptide backbone is enriched with respect to serine, threonine, proline 
and alanine that together comprise 65% of the amino acids in this molecule. 
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Figure 2. Schematic representation of an MG2 molecule 
The red lines represent the 5 potential N-glycosylation sites that occur in the 
secreted apomucin. The blue lines represent some of the putative O-
glycosylation sites. The N-terminal region (D1, D2) is composed of 144 amino 
acids and is represented by the blue box. The tandem repeat region (D3) 
contains 138 amino acids and is represented by the red box, and the C-terminal 
region (D4, D5) containing 75 amino acids is represented by the green box. 
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Chemical analysis and semi-empirical prediction algorithms indicate that 
86 of 105 potential O-glycosylation sites (Ser + Thr residues) in the MG2 
apomucin should be glycosylated (Gururaja et al., 1998). N-linked glycans are 
attached to the side chain of asparagine residues found in the consensus 
sequence, X-Asn-X-Thr- or X-Asn-X-Ser-, and 3 such sequences occur in the N-
terminal region and 2 such sequences occur in the C-terminal region of the MG2 
apomucin. The carbohydrate side chains in MG2 range in length from 2-7 
residues and the majority of the monosaccharides are N-acetylglucosamine, N-
acetylgalactosamine, galactose, fucose and sialic acid (Prakobphol et al., 1982). 
Gururaja and co-workers have proposed that the MG2 molecule is 
organized into 5 distinct domains (D). D-1 is located in the N-terminal region 
containing the only two cysteines in the molecule. This region also contains a 
leucine-zipper segment. D-2 is a moderately glycosylated domain while D-3 is a 
heavily glycosylated region containing five or six tandem repeats comprised each 
of 23 amino acid residues. D-4 is a second heavily glycosylated region 
downstream from the tandem repeats and D-5 is the extreme C-terminal domain 
which also contains a leucine zipper segment (Gururaja et al., 1998). A histatin-
like sequence occurs in domain 1 (residues 23-37) and a synthetic peptide 
corresponding to this sequence was reported to exhibit candidacidal activity 
(Gururaja et al., 1999).  
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2.11.3. MG2 isoforms and multimerization 
Two isoforms of MG2, which vary in their sialic acid to fucose ratios, were 
isolated from SMSL secretion by ion exchange chromatography and were named 
MG2a and MG2b (Ramasubbu et al., 1991). The chemical composition of MG2a 
and MG2b was similar in different individuals. It has long been assumed that 
MG2 in whole saliva and salivary secretions exist as a monomer although a 
recent study reported that MG2 could form dimers and tetramers in vitro 
(Mehrotra et al., 1998). It has been reported that a recombinant protein 
expressed in Escherichia coli comprising the N-terminal 144 residues of MG2 
can form dimers that are stable when analyzed by SDS-PAGE under reducing 
conditions (Liu et al., 2000). 
 
2.11.4. MG2 functions 
MG2 is present in the biofilm that covers oral surfaces preventing 
desiccation of soft tissues and aiding in mastication, swallowing and speech 
(Collins and Dawes, 1987). This salivary mucin was reported to have affinity for 
hydroxyapatite (Tabak et al., 1985), be present in a short term (10-60 min) 
pellicle formed on cementum (Fisher et al., 1987) but was not considered to be a 
component of the 2-hour acquired enamel pellicle (Al-Hashimi and Levine, 1989). 
MG2 has been shown to exhibit candidacidal activity (Gururaja et al., 1999; Liu et 
al., 2000) and to kill the periodontal pathogen, A. actinomycetemcomitans  (Liu et 
al., 2002). Another feature of MG2 was the participation in a heterotypic complex 
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with SIgA and it has been suggested that this interaction may enhance the anti-
bacterial properties of this mucin (Biesbrock et al., 1991).  
  MG2 interacts with a diverse number of oral microbes indicating that this 
mucin is an important component of the innate immune system (Reddy et al., 
1993; Groenink et al., 1996, Liu et al., 1999, 2000, 2002). Earlier studies have 
reported that MG2 can bind and agglutinate a number of strains of oral bacteria 
(Gibbons et al., 1978; Levine et al., 1978; Biesbrock et al., 1991; Lightenberg et 
al., 1992, Stinson and Levine, 1993). Interactions between MG2 and HIV-1 have 
also been reported (Bergey et al., 1994). MG2 binds to several strains of S. 
mutans, the periodontal pathogen A. actinomycetemcomitans and the pathogenic 
yeast, C. albicans (Liu et al., 1999, 2000; in press). Treatment of MG2 with 
neuramidase did not affect binding of A. actinomycetemcomitans suggesting that 
protein-protein interactions were involved in binding (Groenick et al., 1996). 
It is interesting to note that only two cysteine residues exist in the entire 
polypeptide backbone and reduction and alkylation of these residues abolished 
binding of MG2 and also of a recombinant MG2 molecule comprising the N-
terminal 144 residues (rNMUC7) to S. mutans (Liu et al., 1999, 2000). In 
addition, it has been reported that a recombinant fragment of MG2 (residues 1-
86) bound specifically to pili from P. aeruginosa suggesting that binding likely 
involves a region within domain 1 or domain 2 in MG2 apomucin (Reddy, 1998). 
These results point to the existence of a binding motif in MG2 localized in the N-
terminal region and that the cysteine residues should be part of this bacterial-
binding motif (Liu et al., 1999).   
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3. Random peptide display library 
In the postgenomic era, the rapid accumulation of genetic information 
increases the requirement of a general experimental approach suitable for large 
scale profiling of the whole proteome. Biomolecular display technologies, which 
allow expressing a large pool of biomolecules, are extremely useful for assessing 
and analyzing protein diversity and interaction profiles. A random peptide display 
library can be made by cloning degenerate oligonucleotides encoding random 
peptide sequences into a vector that will enable the peptide to be expressed on 
the surface of a phage or bacteria (Lu et al., 1995). The fusion proteins (prey) 
can then be exposed to an immobilized target protein (bait) and selection of 
polypeptide binders can be used to characterize protein-protein (prey/bait) 
interactions at the molecular level. 
Selection can be obtained by a simple process called panning (Scott and 
Smith, 1990) in which cells expressing interactive peptides bind to the target 
protein while cells expressing peptides that do not interact with the target protein 
are washed away. Repeating the panning process will further screen the library, 
resulting in enrichment in cells that express specific peptide sequences. A 
schematic representation illustrating this positive selection is shown in Figure 3.  
Peptides with affinity for a variety of biomolecules have been successfully 
identified in studies relating to cancer, viral infections, vaccinology and other 
areas (Samuelson et al., 2002). The applications of this technique show great 
potential for biotechnological and medical studies. 
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Figure 3. Peptide display library positive selection  
A) E. coli cells expressing different dodecapeptides (represented by blue 
triangles, yellow circles or red squares) are exposed to a target protein.  
B) Cells expressing a dodecapeptide (red squares) that specifically interacts with 
the target protein are selected. 
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3.1. Peptide display applications 
One of the earlier applications of random peptide display was to map the 
epitopes of monoclonal antibodies (Philippe et al., 1993; Sibille and Strosberg, 
1997; Murthy et al., 1998). The panning procedure was carried out using 
monoclonal antibodies as target proteins and after repeated cycles of panning, 
the selected clones contained peptides with amino acid sequences that reveal 
the epitope against which they were directed. In allergy research, antibody 
fragments were used to address fundamental issues regarding the development 
of IgE antibodies in allergic patients, at both the molecular and structural level, 
showing again the therapeutic potential of this technology (Edwards et al., 2000). 
In cancer research, since most tumor antigens are not entirely foreign and are 
expressed to some extent on normal tissues as well, a peptide mimic may have 
the potential to generate greater immune responses than that induced by “self” 
peptides. Therefore, the applications of peptide mimetics for cancer 
immunotherapy may ultimately prove to be useful in the development of vaccines 
(Apostolopoulos et al., 2002). 
Panning with a target protein and peptide display library have also been 
used to investigate non-antigen-antibody interactions. Random peptide display 
library technology has identified a specific ligand for the alpha-5-beta-1 integrin 
(Koivunen et al., 1994), a peptide containing a structural and functional mimic of 
an RGD-binding site on integrins (Pasqualini et al., 1995), a peptide motif 
composed of a specific subset of amino acids (Blond-Elguindi et al., 1993; Brown 
et al., 2000) and peptide sequences from a large number of proteins that 
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potentially interact with chromatin high mobility group protein 1 (Dintilhac and 
Bernues, 2001). In summary, peptide display library is a powerful tool in the 
investigation of protein-protein interactions. 
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Objectives 
1. Characterization of cysteine residues in MG2 
Salivary mucin MG2 has been reported to bind to oral microbes and 
disruption of binding by reduction and alkylation suggests that the cysteine 
residues occur in a structural motif necessary for mucin/bacterial interactions 
(Liu et al., 1999). Consequently, the physical state of the cysteines in MG2 is 
of considerable interest with respect to this salivary mucin function. To date, it 
is not known whether cysteines in the binding domain in the N-terminal region 
of MG2 exist in the disulfide or dithiol form and the present study was 
undertaken to address this question.  
 
2. Investigation of heterotypic complexes of SIgA and MG2 by peptide 
display 
The function of the majority of proteins is related to their ability to interact 
with other specific molecules. Protein-protein interactions integrate cells into 
tissues, maintain homeostasis, regulate embryonic remodeling, participate in 
wound healing and pathological conditions (Nguyen and D'Amore, 2001). 
Salivary proteins are involved in the maintenance of the oral health and 
interactions among these proteins are necessary in the protection of mucosal 
surfaces since they are the main entrance for most of the pathogenic 
microorganisms that infect humans. The occurrence of heterotypic complexes 
involving SIgA and MG2 may enhance the anti-microbial properties of either 
member of this complex (Biesbrock et al., 1991).  Complexing between SIgA 
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and salivary agglutinins, and SIgA and lactoferrin, were reported to increase 
the properties of these two components of the innate immune system in the 
oral cavity (Rundegren and Arnold, 1989; Kilian et al., 1988). In the present 
study we used a random peptide display library to select for peptide 
sequences that can interact with SIgA and MG2. Sequence analysis of 
interactive peptides should reveal potential candidates that may participate in 
the formation of heterotypic complexes in vivo.  
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Materials and Methods 
 
1. Characterization of the cysteine residues in MG2  
1.1. Saliva collection and ultrafiltration 
Stock solutions: 
1 M Tris-HCl, pH 7.5  
 - 400 ml of Deionized water 
 - 60.5 g Tris base 
 - Stir into solution 
 - Adjust pH to 7.5 with concentrated HCl 
 - Add Deionized water to 500 ml 
 
0.5 M EDTA, pH 8.0 
 
 - 93.05 g Na2EDTA 
 - 400 ml of Deionized water 
 -10 g NaOH pellets 
 - Stir into solution 
 - Adjust pH to 8.0 with 1 M NaOH 
 - Add Deionized water to 500 ml 
 
Buffer A (50 mM Tris-HCl, pH 7.5, containing 5 mM EDTA, 0.01% sodium azide 
and 4 M guanidine hydrochloride) 
 
- 50 ml of 1 M Tris-HCl, pH 7.5 
- 650 ml Deionized water  
- 382 g Guanidine-HCl 
- Stir into solution 
- 0 ml 0.5 M EDTA, pH 8.0 
- 0.2 g Sodium azide 
- Add Deionized water to 1000 ml 
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Human submandibular/sublingual secretion (SMSL) was obtained from 
three donors (26-35 years old) who provided informed consent according to a 
protocol approved by the Institutional Review Board at Boston University Medical 
Center. Stimulated SMSL was collected between 10:00 AM and 11:00 AM, using 
sour lemon drops as stimulus, into iced-chilled 50 ml graduated tubes, with use 
of custom fitted devices as described (Jensen et al., 1992). Subjects were seated 
and 50 ml samples per day were collected from each individual over a three-day 
period obtaining a final volume of 450 ml of SMSL. After each collection, an 
equal volume of 2X Buffer A was added to the 50 ml samples from each donor 
and the mixture was gently stirred. The final concentration of the 900 ml sample 
(450 ml SMSL + 450 ml 2X buffer A) was 50 mM Tris-HCl, pH 7.5, containing 5 
mM EDTA, 0.01% sodium azide and 4 M guanidine hydrochloride. The sample 
was concentrated to 30 ml by passage through an XM-100 filter (100 kDa cutoff) 
using an Amicon High-Performance System (model TGF10; Amicon, Beverly, 
MA) at 10 psi under nitrogen gas.  
 
1.2. Purification of MG2 
The solution used is given below: 
Buffer A prepared as described above 
 
The XM-100 retentate (30 ml) was subjected to gel filtration 
chromatography on a Sepharose CL-2B column (5 x 84 cm) equilibrated with 50 
mM Tris-HCl, pH 7.5, containing 5 mM EDTA, 0.01% sodium azide and 4 M 
guanidine hydrochloride (buffer A). The flow rate was 5 ml/min, 10 ml fractions 
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were collected and column eluate was continuously monitored at 280 nm using a 
Uvicord SII (Pharmacia, Piscatway, NJ). MG2 in column fractions was identified 
by indirect ELISAs using a rabbit polyclonal anti-MG2 peptide antibody (Liu et al., 
1999) and mucin-containing fractions were pooled and concentrated to 10 ml 
using a Centriprep 50 concentrator (Amicon) using a Sorvall SS-34 rotor (Kendro 
Laboratory Products, Newton, CT) at 3,500 rpm at 4oC. The concentrated MG2 
sample was chromatographed in 1.0 ml aliquots on a Superose 6 prep grade 
column (1.6 x 58 cm; Pharmacia) equilibrated with buffer A. The flow rate was 
0.4 ml/min, 1.6 ml fractions were collected, and column eluate was continuously 
monitored at 254 nm and 280 nm using a FPLC system (Pharmacia). MG2 
containing fractions identified by indirect ELISAs were pooled and concentrated 
to a volume of 2.0 ml using a Centripep 50 device as above. The concentrated 
MG2 sample was chromatographed in 0.2 ml aliquots on a Superose 6 column (1 
x 30 cm; Pharmacia). The flow rate was 0.4 ml/min, 0.4 ml fractions were 
collected, and column eluate was continuously monitored at 254 nm and 280 nm 
using the FPLC system. MG2 containing fractions were detected by indirect 
ELISAs and samples from 10 runs were pooled, concentrated to 1 ml and 
rechromatographed on the same column using the same parameters. MG2 
containing fractions were pooled, dialyzed against distilled water and the purity of 
the MG2 preparation was assessed by on 10% SDS-polyacrylamide gels stained 
with periodate acid-Schiff (PAS) reagent and conterstained with silver. The 
concentration of purified MG2 was determined by quantitative amino acid 
analysis and the resulting sample stored at –20oC until used. 
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1.3. Indirect ELISA 
The solutions used are given below: 
 
TBS (10 mM Tris-HCl, pH 8.0 containing 150 mM NaCl ) 
- 900 ml of Deionized water 
- 1.21 g Tris base 
- 8.76 g NaCl 
- Stir into solution 
- Adjust pH to 8.0 with concentrated HCl 
- Deionized water to 1000 ml 
 
TBST (10 mM Tris-HCl, pH 8.0 containing 150 mM NaCl and 0.1% Tween 20) 
- Same as TBS with the addition of 1 ml of Tween 20 
 
PNPP Buffer (0.1 M Glycine, 1 mM MgCl2 and 1 mM ZnCl2, pH 10.4) 
- 900 ml of Deionized water 
- 7.51 g Glycine 
- 203 mg MgCl2 
- 136 mg ZnCl2 
- Adjust pH to 10.4 
- Deionized water to 1000 ml 
 
        For identification of MG2 containing fractions during the purification 
procedure, Immulon 4 High Binding 96-Well Microtiter Plates (Dynex 
Technologies, Chantilly, VA) were coated with aliquots of column fractions (50 μl) 
and incubated at 4oC overnight. Plates were washed (300 μl/well) with TBS three 
times and blocked (250 μl/well) with 3% bovine serum albumin (BSA; Sigma, St 
Louis, MO) in TBST for 1 hour at 37oC. Plates were washed three times (300 
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μl/well) with TBST and incubated (100 μl/well) with a rabbit polyclonal antibody 
(against a synthetic peptide corresponding to amino acid residues 47-63 of MG2) 
diluted1:1000 in 1% BSA/TBST for 1 hour at 37oC. Plates were washed as above 
and incubated (100 μl/well) with a goat anti-rabbit IgG conjugated to alkaline 
phosphatase (Jackson Immuno Research Laboratories,Inc, West Grove, PA)  
diluted 1:7500 in 1% BSA/TBST for 1 hour at room temperature (RT). Plates 
were washed and color development was obtained with p-nitrophenyl phosphate 
disodium (1 mg/ml; 100 μl/well) in PNPP buffer. Plates were read at 405 nm on a 
Dynex MRX Plate Reader (Dynex Technologies). 
 
1.4. Amino acid analysis 
The solution used in is given below: 
 
Amino acid analysis buffer (2% Sodium citrate, 1% HCl and 0.1% Benzoic acid) 
- 2 g Sodium citrate 
- 1 ml HCl 
- 0.1 ml Benzoic acid 
- Deionized water to 100 ml 
 
Three aliquots of purified MG2 were placed in glass ampoules, dissolved 
in 400 μl of 6N HCl and frozen in a dry ice-acetone bath. After freezing was 
accomplished, the ampoules were evacuated, flame-sealed and incubated in a 
Heat Block (VWR Scientific, Bridgeport, NJ) for 24 hour at 105oC. Ampoules 
were unsealed, placed in a water bath (100oC) and hydrolysates were 
evaporated to dryness under a stream of nitrogen. Dried samples were 
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resuspended in 400 μl of distilled water and dried as above. This step was 
repeated once. Finally, dried samples were dissolved in 400 μl of amino acid 
analysis buffer, filtered with 0.45 μm syringe filters (Fisher Scientific) and 
subjected to amino acid analysis on a Beckman System 6300 amino acid 
analyzer.   
 
1.5. SDS-PAGE gels 
The solutions used are given below: 
 
1.5 M Tris-HCl buffer, pH 8.8 
- 27.2 g Tris base 
- 80 ml Deionized water 
- Stir into solution 
- Adjust pH to 8.8 with concentrated HCl 
- Deionized water to 150 ml and store at 4oC 
 
0.5 M Tris-HCl buffer, pH 6.8 
- 6.0 g Tris base 
- 60 ml Deionized water 
- Stir into solution 
- Adjust pH to 6.8 with concentrated HCl 
- Deionized water to 100 ml and store at 4oC 
 
10% SDS 
- 10 g SDS 
- Deionized water to 100 ml 
- Stir into solution 
 
 
 
 43 
Acrylamide/Bis 
- 87.6 g Acrylamide 
- 2.4 g N’N’-methylene-bis-acrylamide 
- Deionized water to 300 ml 
- Filter and store at 4oC in the dark  
 
10% Ammonium persulfate 
- 100 mg Ammonium persulfate 
- 1 ml Deionized water   
- Stir into solution (prepare fresh)  
 
Laemmli sample buffer (62.5 mM Tris-HCl, pH 6.8 containing 0.1% Glycerol, 2% 
SDS and 0.0125% Bromophenol blue) 
- 4 ml Deionized water 
-1.0 ml 0.5 M Tris-HCl, pH 6.8   
- 0.8 ml Glycerol 
- 1.6 ml 10% SDS 
- 0.2% (w/v) Bromophenol blue  
- Stir into solution 
 
Running buffer (25 mM Tris-HCl, pH 8.3, containing 192 mM glycine and 0.1% 
SDS). 
- 1.8 g Tris base 
- 8.64 g Glycine 
- 0.6 g SDS 
- Deionized water to 600 ml 
- Stir into solution  
- Store at 4oC.  
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PAS Fixative solution (40% Ethanol containing 5% Acetic acid) 
- 400 ml 100% Ethanol 
- 50 ml Glacial acetic acid 
- 550 ml Deionized water  
 
PAS Reductive solution (30 mM Periodic acid containing 5% Acetic acid) 
- 0.7 g Periodic Acid 
- 5 ml Glacial acetic acid 
- 95 ml Deionized water 
 
Schiff reagent (0.5% Pararosaniline containing 0.1 N HCl, 0.85% Sodium 
metabisulfite, and 0.15% activated charcoal) 
- 2.5 g Pararosaniline 
- 500 ml Deionized water (100oC) 
- Mix and cool to 50 oC 
- 50 ml 1 N HCl 
- 4.25 g Sodium metabisulfite 
- 0.75 g Charcoal 
- Stir (5 min) and filter twice  
 
Potassium Metabisulfite Solution (10 mM Potassium metabisulfite, 40% Ethanol 
and 5% Acetic acid) 
- 0.8 g Potassium metabisulfite 
- 160 ml of 100% Ethanol 
- 20 ml of Glacial acetic acid 
- 220 ml of Deionized water 
 
PAS Destain Solution (40% Ethanol containing 5% Acetic acid) 
- 550 ml Deionized water 
- 400 ml 100% Ethanol 
- 50 ml Glacial acetic acid 
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Silver Fixative Enhancer Solution  
- 50 ml Methanol     
- 10 ml Glacial acetic acid    
- 5 ml Fixative enhancer concentrate  
- 35 ml Deionized water      
 
Silver Developing Solution 
- 2.5 ml Silver complex solution   
- 2.5 ml Reduction moderator solution  
- 2.5 ml Image developing reagent  
- 17.5 ml Deionized water      
- To the above, 25 ml of Development accelerator reagent was added with gentle 
stirring. 
 
A Mini-Protean II dual slab gel electrophoresis system (BIO-RAD, 
Hercules, CA) was used to perform sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Separating gels of 7.5% (4.85 ml of H2O, 2.5 ml of 
1.5 M Tris-HCl, pH 8.8, 100 μl of 10% SDS, 2.5 ml of 30% 
acrylamide/bisacrylamide, 50 μl of 10% ammonium persulfate and 5 μl TEMED 
were combined and gently mixed) and stacking gels of 5% (5.67 ml of H2O, 2.5 
ml of 0.5 M Tris-HCl, pH 6.8, 100 μl of 10% SDS, 1.67 ml of 30% 
acrylamide/bisacrylamide, 50 μl of 10% ammonium persulfate and 10 μl TEMED 
were combined and mixed) were prepared and used. Samples were dissolved in 
20 μl of Laemmli sample buffer under reducing (containing 0.05% β-
mercaptoethanol) or non-reducing (without 0.05% β- mercaptoethanol) 
conditions, heated in hot water at 95oC for 5 min, cooled to RT, and loaded onto 
gels. Standards (SDS-PAGE, broad range, prestained; BIO-RAD) were included 
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on gels. Electrophoresis was conducted in running buffer at 80 volts for 1.5 hours 
at RT. Gels were stained by the PAS method (Segrest and Jackson, 1972) and 
counterstained with silver. 
 For PAS staining, gels were fixed in 200 ml of PAS Fixative Solution for 24 
hours with gentle shaking at RT. Glycoproteins on gels were oxidized in 200 ml 
of for 3 hours with gentle shaking at RT and were reduced in 200 ml of PAS 
Reductive Solution for 30 min. The solution was changed and reduction allowed 
to proceed for an additional 1.5 hours with gentle shaking at RT. Staining was 
performed for 18 hours with gentle shaking at RT with 100 ml of Schiff reagent  
that had been filtered twice through a Corning 0.22 μm cellulose-acetate, low 
protein binding vacuum filter (Fisher). Gels were incubated with Potassium 
Metabisulfite Solution for 1.5 h with gentle shaking at 55oC. Finally, gels were 
destained in 250 ml of 40% ethanol containing 5% acetic acid. 
  Gels stained with PAS were counterstained with silver using the Silver 
Stain Plus Kit (BIO-RAD) according to manufacturers instructions. Briefly, gels 
were fixed with 100 ml of Silver Fixative Enhancer Solution (for 20 min with 
gentle shaking at RT. The solution was decanted and gels were rinsed twice with 
200 ml of water for 10 min with gentle shaking. Gels were placed in 25 ml of 
Silver Developing Solution and incubated in this solution with gentle shaking at 
RT. The reaction was stopped when the desired stain intensity was obtained by 
placing the gel in 5% acetic acid.  
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1.6. Western blots 
The solutions used are given below: 
 
Transfer buffer (25 mM Tris, 192 mM Glycine containing 20% Methanol) 
- 3.03 g Tris base 
-14.4 g Glycine 
- 600 ml Deionized water      
- 200 ml Methanol 
- Deionized water to 1000 ml 
 
TBST (as previously described) 
 
Alkaline Phosphatase (AP) buffer (100 mM Tris-HCl, pH 9.5, 100 mM NaCl and 5 
mM MgCl2) 
- 12.12 g Tris base 
- 5.84 g NaCl 
- 1.01 g MgCl2 
- Deionized water to 1000 ml 
 
In some experiments, proteins in gels were transferred (transfer buffer) to 
nitrocellulose membrane (Protran, Schleicher and Schuell, Keene, NH) and 
examined by Western blotting. Transfers were accomplished using a Mini Trans-
Blot Transfer Cell (BIO-RAD) at 30 volts overnight at 4oC. Blots were then 
equilibrated in 20 ml of TBST for 20 min with gentle shaking at RT and blocked in 
10 ml of 5% milk (non-fat, dried; Carnation, Nestle) in TBST for 1 hour with gentle 
shaking at RT. Blots were washed three times (10 min/each) with 20 ml of TBST 
and probed with a rabbit polyclonal anti-MG2 peptide antibody diluted 1:1000 in 
10 ml of 1% milk in TBST for 1 hour with gentle shaking at RT. Blots were 
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washed as above and probed with a goat anti-rabbit IgG conjugated to alkaline 
phosphatase (Jackson Immuno Research Laboratories,Inc, West Grove, PA)  
diluted 1:7500 in 10 ml of 1% milk in TBST for 1 hour with gentle shaking at RT. 
Blots were washed as above and transferred to 10 ml of AP buffer containing 33 
μl of 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) and 66 μl of nitro blue 
tetrazolium (NBT) to obtain color development (Promega, Madison, WI). Color 
development was stopped by washing blots in distilled water.  
 
1.7. Covalent modification 
The solution used is given below: 
 
Buffer U (100 mM Tris-HCl, pH 8.3, containing 1 mM EDTA and 8 M Urea) 
- 12.12 g Tris base 
- 186.1 mg EDTA 
- 480.5 g Urea 
- Deionized water to 1000 ml  
- Stir into solution 
- Adjust pH to 8.3 with concentrated HCl 
 
Reduction and alkylation: MG2 (50 g) in water was evaporated to 
dryness in a SpeedVac, taken up in 150 l of buffer U containing dithiotreitol (2 
fold excess over the potential disulfide bonds) and reduction was carried out in a 
1.8 ml screw cap tube incubated at 37oC for 1 hour. The reduced mucin sample 
was alkylated by addition of 3 l of buffer U containing iodoacetamide (1.1 fold 
molar ratio over the thiol groups in the solution) and 14C-iodoacetamide (5 Ci; 
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59 mCi/mmol; Amersham/Pharmacia) was added. The reaction mixture was 
placed in a 1.8 ml screw cap tube, flushed with nitrogen gas and incubated in the 
dark at 37oC for 1 hour. The reaction was stopped by the addition of 1.6 l β-
mercaptoethanol and the reduced and alkylated sample (RA-MG2) was stored at 
–20oC until used. 
Direct alkylation: MG2 (50 g) in water was evaporated to dryness in a 
SpeedVac, taken up in 150 l of buffer U and alkylated as described above. The 
alkylated sample (A-MG2) was stored at –20oC until used.    
 
1.8. Gel filtration of covalently modified MG2 
The solution used is given below: 
 
Buffer A prepared as described above 
 
Radiolabeled samples of RA-MG2 or A-MG2 (50 g) were evaporated to 
dryness in a SpeedVac, suspended in 200 l of buffer A and chromatographed 
on a Superose 6 column equilibrated in the same buffer. The flow rate was 0.4 
ml/min, 0.4 ml fractions were collected and column eluate was continuously 
monitored at 254 nm  and 280 nm. Column fractions were examined for MG2 
immunoreactivity by indirect ELISAs using a rabbit polyclonal anti-MG2 peptide 
antibody as described above. In order to detect radioactivity aliquots (0.1 ml) 
from column fractions were placed in 0.9 ml of a LSC cocktail (ULTIMA FLO AP; 
Packard, Perkin Elmer, Wellesley, MA) and samples were assayed for 
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radioactivity in a liquid scintillation counter (1217 RACKBETA LKB, WALLAC, 
Perkin Elmer). 
 
1.9. Enzymatic digestion and peptide isolation 
The solutions used are given below: 
Digestion Buffer (25 mM Tris-HCl, pH 8.5, containing 1 mM EDTA) 
- 3.03 Tris base 
-186.1 mg EDTA 
- Deionized water to 1000 ml  
- Stir into solution 
- Adjust pH to 8.5 with concentrated HCl 
 
Solvent A (0.1% Trifluoroacetic acid in water) 
- 1 ml Trifluroacetic acid 
- 999 ml Deionized water 
 
Solvent B (0.1% Trifluoroacetic acid, 80% Acetonitrile, 19.9% water) 
- 1 ml Trifluoroacetic acid 
- 800 ml Acetonitrile 
- 199 ml Deionized water 
 
In order to identify alkylated cysteines, covalently modified MG2 was 
digested with Endoproteinase Lys-C (Roche, Indianopolis, IN) and derived 
peptides were separated by reversed phase high performance liquid 
chromatography (RP-HPLC) using a Waters liquid chromatography system 
(Waters, Hopkinton, MA). A-MG2 (50 g) was dissolved in 100 μl of digestion 
buffer. Endoproteinase Lys-C (3 l; 1 mg/ml) was added and the reaction mixture 
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was incubated for 4 hours at 37oC. At this time a second 3 l aliquot of enzyme 
was added and incubation was continued for an additional 2 hours at 37oC. The 
final ratio of enzyme to substrate was 1:25 (taking into account that MG2 is 
comprised of 30% protein by weight).  Subsequently, the reaction mixture was 
chromatographed on a Vydac C18 column (300 Ao, 4.6 x 150 mm; VYDAC/The 
Separations Group, Hesperia, CA) developed with a gradient from 100% solvent 
A (0.1% trifluoroacetic acid in water) to 40% solvent B for 40 min and then to 
100% solvent B over the next 40 min. The flow rate was 1.0 ml/min, 1.5 ml 
fractions were collected and column eluate was continuously monitored at 229 
nm. A portion (0.5 ml) of each fraction was assayed for radioactivity in a liquid 
scintillation counter as described above. 
 
1.10. Mass spectrometry 
Enzymatic digested peptides of A-MG2 column fractions that showed the 
presence of radioactivity were examined by matrix assisted laser desorption 
ionization (MALDI) time of flight (TOF) mass spectrometry on a Micromass 
Quattro 2 triple quadrupole mass spectrometer equipped with a z-spray source. 
In this technique, samples are mixed with a huge excess of matrix material (-
cyano-4-hydroxycinnamic acid). The matrix absorbs the laser energy and emits 
heat, causing the vaporization and ionization of the sample. Each ion will have 
the same initial kinetic energy, but a speed that varies according to the mass. A 
spectrometer will determine each ion mass-to-charge (m/z) ratio based on their 
time of flight and the observed peptides m/z can be analyzed.  
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2.0. Investigation of heterotypic complexes of SIgA and MG2 using a 
peptide display library.  
 
2.1. Test proteins 
A mouse monoclonal antibody directed against human Interleukin 8 (IL-8) 
was purchased from BIODESIGN (Saco, ME) and purified human sIgA (from 
colostrum) was purchased from Accurate Chemical & Scientific Corporation 
(Westbury, NY). Salivary mucin MG2 was isolated from human 
submandibular/sublingual secretions as described above.  
 
2.2. Peptide display 
A Flitrx peptide display library was purchased from Invitrogen (Carlsbad, 
CA). This library consists of Escherichia coli cells each containing a different 
pFlitrx plasmid engineered to express a fusion protein containing a 
dodecapeptide inserted into the active site loop of thioredoxin which itself was 
inserted into a dispensable region of the flagellin gene. A schematic 
representation of an Escherichia coli cell containing the pFlitrx plasmid is shown 
in Figure 4. The gene for the fusion protein is under the control of the lambda cI 
repressor located in the bacterial chromosome. Addition of tryptophan to the 
growth medium will block expression of the lambda cI repressor and will allow 
transcription of the gene for flagellin-thioredoxin-dodecapeptide fusion protein. 
The fusion protein becomes an integral part of the flagellar filaments on the 
bacterial cell surface and the dodecapeptides become available to interact with a  
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Figure 4. Schematic representation of E. coli cells containing the pFlitrx 
plasmid  
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Figure 4. Schematic representation of E. coli cells containing the pFlitrx 
plasmid 
Sequences encoding random dodecapeptides (green) were inserted into the trxA 
gene (orange) that was inserted into a dispensable region of the flicC gene 
(yellow). The trxA gene encodes for thioredoxin and the flicC gene for flagellin 
(major protein component of flagellum).  
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target protein. A schematic representation of the flagellin-thioredoxin-
dodecapeptide fusion protein is shown in Figure 5. 
 
2.3. Dodecapeptide expression 
The solutions and culture medium used are given below: 
 
10X M9 Salts (423 mM Na2 HPO4, 220 mM KH2PO4, 85 mM NaCl and 187 mM 
NH4Cl in 1000 ml of H2O) 
- 60 g Na2HPO4 
- 30 g KH2PO4 
- 5 g NaCl 
-10 g NH4Cl 
- Dissolve in 900 ml of Deionized water 
- Adjust pH to 7.4 
- Deionized water to 1000 ml 
- Autoclave (20 min; liquid cycle; store at RT) 
 
1M MgCl2 
- 20.33 g MgCl2 
- Dissolve in 100 ml of Deionized water 
- Autoclave (20 min; liquid cycle; store at RT) 
 
100 mg/ml Ampicillin 
- 1.0 g Ampicillin 
- Dissolve in 10 ml of Deionized water 
- Filter-sterilize; store at -20oC 
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Figure 5. Dodecapeptide expression 
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Dodecapeptide
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Figure 5. Schematic representation of dodecapeptide expression 
Dodecapeptides (green) are located in the active site loop of thioredoxin 
(orange). This constrains both the N- and C- terminal ends of the dodecapeptide 
resulting in a well-defined structure that will be available to interact with a target 
protein. Flagellin is represented by the red line. 
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20% Glucose 
- 20.0 g glucose 
- Dissolve in 100 ml of Deionized water 
- Filter-sterilize; store at RT 
 
10 mg/ml L-Tryptophan 
- 100 mg L-tryptophan 
- Dissolve in 10 ml of Deionized water 
- Filter-sterilize; store at 4oC in an amber bottle 
 
IMC medium (1X M9, 0.2% Casamino Acids, 0.5% Glucose, 1 mM MgCl2 and 
100 μg/ml Ampicillin) 
- 2 g Casamino acids 
- Dissolve in 875 ml of deioinized water 
- Autoclave (20 min; liquid cycle) 
- Cool down to ~ 50oC 
- 100 ml 10X M9 Salts 
-1 ml 1M MgCl2 
- 25 ml 20% Glucose 
-1 ml 100 mg/ml Ampicillin 
- Mix and store at 4oC 
 
Briefly, one vial of the Flitrx library was inoculated in 50 ml of IMC medium 
and grown with shaking (225 rpm) to stationary phase (OD600 greater than 3.0) 
overnight at 25oC. To induce expression of random dodecapeptides, 1010 cells 
from the overnight culture were inoculated into 50 ml of fresh IMC medium 
containing 100 μg/ml of tryptophan and grown at 25oC with shaking (225 rpm) for 
6 hours. 
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2.4. Immobilization of target protein and blocking procedure 
The solutions used are given below: 
 
5 M NaCl 
- 5.84 g NaCl 
- Deionized water to 100 ml 
 
20% α-Methyl mannoside 
- 20 g α-Methyl mannoside 
- Deionized water to 100 ml 
 
Blocking Solution (IMC medium containing 1% dry milk, 150 mM NaCl and 1% -
Methyl mannoside) 
- 0.1 g Nonfat, dry milk 
- 300 μl 5M NaCl 
- 500 μl 20% α-Methyl mannoside 
- 9.2 ml IMC medium 
 
A 60 mm tissue culture plate (Nunclon Delta; Fisher) was coated with 20 
µg of target protein (anti-IL8, MG2 or sIgA) dissolved in 1 ml of sterile water and 
the plate was agitated at 50 rpm on a orbital shaker (Innova 4000, New 
Brunswick Scientific, Edison, NJ) for 1 hour at RT. The plate was rinsed with 10 
ml of sterile water, 10 ml of blocking solution (IMC medium containing 1% dry 
milk, 150 mM NaCl and 1% -methyl mannoside) was added and the plate was 
agitated at 50 rpm for 1 h at RT. Addition of -methyl mannoside prevented 
unwanted adherence of E. coli cells to target proteins via lectin-like interactions. 
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2.5. Panning procedure 
The solutions and culture medium used are given below: 
 
Washing Solution (IMC medium containing 1% -Methyl mannoside) 
- 2.5 ml of 20% α-Methyl mannoside 
- 47.5 ml IMC Medium  
 
IMC medium (prepared as described above) 
 
After the 6 hour induction period, 10 ml from the induced culture was 
removed and added to 0.1 g dry milk, 300 l 5 M NaCl and 500 l 20% -methyl 
mannoside. The blocking solution was decanted from the plate and 10 ml of 
induced cells were prepared as above was added. The plate was agitated at 50 
rpm for 1 min and then incubated without shaking for 1 hour at RT. The bacterial 
culture medium containing unbound cells was decanted and the plate was 
washed with 10 ml of (WS) at 50 rpm for 5 min. WS was decanted and the 
washing procedure was repeated 4 times. After the final treatment with WS, 
bound cells were eluted into the small residual volume of WS by vigorously 
vortexing the plate for 30 sec.  IMC medium (10 ml) was added to the plate, the 
cell suspension was transferred to a sterile 125 ml Erlenmeyer flask and cells 
were grown with shaking (225 rpm) overnight at 25oC. The induction, 
immobilization of target protein, plate blocking and panning was repeated for 11 
days. The panning procedure is schematically shown in Figure 6. 
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Figure 6. Panning protocol 
1- Plate target protein
2- Block Plate
3- Bind Flitrx Library
4- Wash off unbound 
cells
5- Elute bound cells
6- Grow eluted cells
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Figure 6. Panning protocol.   
The sequence of procedures involved in 1 round of panning consists of, coating a 
petri plate with a target protein (1), blocking the plate (2), exposing the target 
protein to 1010 cells expressing dodecapeptides (3), washing off cells that do not 
express dodecapeptides that bind to the target protein (4), eluting (5) and 
growing cells (6) containing dodecapeptides that interacted with the target 
protein. This procedure can be repeated in subsequent days to enrich the library 
with cells expressing dodecapeptides that interact specifically with the target 
protein. 
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2.6. Isolation of positive clones 
The plates used are given below: 
 
RMG plates (1X M9 Salts, 2% Casamino Acids, 0.5% Glucose, 1 mM MgCl2, 100 
g/ml Ampicillin) 
- 20 g Casamino acids 
- 15 g Agar 
- Dissolve in 875 ml of Deionized water 
- Autoclave (20 min; liquid cycle) 
- Cool down to ~ 50oC 
- 100 ml 10X M9 Salts 
-1 ml 1M MgCl2 
- 25 ml 20% Glucose 
-1 ml 100 mg/ml Ampicillin 
- Mix and pour plates (store in the dark at 4oC) 
 
Overnight cultures from each day of panning were streaked onto RMG 
plates to select single colonies. Plates were incubated overnight at 30oC. 
Glycerol stocks (20%) prepared with both single colonies and panned libraries 
from each day were stored at –80oC until used. 
 
2.7. Gel electrophoresis and blotting 
The solutions and culture medium used are given below or were described 
above: 
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RM medium (1X M9 Salts, 2% Casamino Acids, 1% Glycerol, 1 mM MgCl2, 100 
g/ml ampicillin) 
- 20 g Casamino acids 
- 10 ml 100% Glycerol 
- Dissolve in 890 ml of Deionized water 
- Autoclave (20 min; liquid cycle) 
- Cool down to ~ 50oC 
- 100 ml 10X M9 Salts 
-1 ml 1M MgCl2 
-1 ml 100 mg/ml Ampicillin 
- Mix and store at 4oC 
 
Isolated colonies or libraries from glycerol stocks were inoculated into 10 
ml of RM medium (1X M9 Salts, 0.2% Casamino Acids, 1% glycerol, 1 mM MgCl2 
and 100 g/ml ampicillin) and grown overnight with shaking (225 rpm) at 30oC. 
The OD600 from the overnight cultures was approximately 3.0. An aliquot (40 l) 
from overnight cultures was inoculated into 2 ml of IMC medium containing 
tryptophan. Cells were grown as above to an OD600 of 0.3-0.6 and 1.5 ml were 
transferred to Eppindorf tubes which were centrifuged at 10,000 g for 20 sec. 
Supernatants were decanted and cells were resuspended in 100 l Laemmli 
sample buffer and boiled. Aliquots (5 l) of samples were examined by SDS-
PAGE on 7.5% polyacrylamide gels prepared as described above. In some 
experiments, proteins in gels were transferred electrophoretically to a 
nitrocellulose membrane (Protran) as described above.   
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2.8. Western blots 
The solutions used in this section were described above. 
 
Western blots from gels of cell lysates derived from individual colonies or 
libraries after panning with the anti-IL8 antibody were probed with the anti-IL8 
antibody. Blots were equilibrated in 20 ml of TBST for 20 min with gentle shaking 
at RT and blocked in 10 ml of 5% milk in TBST for 1 hour with gentle shaking at 
RT. Blots were washed three times (10 min/each) with 20 ml TBST and probed 
with a mouse monoclonal anti-IL8 antibody diluted 1:1000 in 10 ml of 1% milk in 
TBST for 1 hour with gentle shaking at RT. Blots were washed as above and 
probed with a goat anti-mouse IgG conjugated to AP (Promega) diluted 1:5000 in 
10 ml of 1% milk in TBST for 1 hour with gentle shaking at RT. Blots were 
washed as above and color development was obtained by addition of BCIP and 
NBT to 10 ml of AP buffer according to manufacturers instructions.   
 
2.9. Far Western blots of sIgA selected dodecapeptides 
The solutions used are given below or were described above: 
 
Buffer F (10 mM Tris-HCl, pH 7.5, containing 100 mM NaCl and 0.1% Tween-20) 
- 900 ml of Deionized water 
- 1.21 g Tris base 
- 5.84 g NaCl 
- Stir into solution 
- Adjust pH to 7.5 with concentrated HCl 
- 1 ml Tween 20 
- Deionized water to 1000 ml 
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Far Western blots from gels of cell lysates derived from individual colonies 
or libraries after panning with sIgA were probed with anti-sIgA antibodies. Blots 
were equilibrated for 15 min with 20 ml of  (buffer F) and blocked with 10 ml of 
5% BSA in buffer F for 1.5 hours at RT. Blots were washed 3 times (10 min each) 
with 20 ml of buffer F and the membrane was incubated with 100 g of sIgA 
dissolved in 10 ml of buffer F for 5 hours with gentle agitation at 4oC. 
Subsequently, blots were washed 6 times with buffer F and incubated with a 
mouse Mab against sIgA ( chain) diluted 1:1000 in 10 ml of 1% BSA in buffer F 
for 1 hour with gentle agitation at RT. After several washes, goat anti-mouse IgG 
conjugated to AP (Promega) diluted 1:5000 in 10 ml of 1% BSA in buffer F was 
added and the membrane was incubated with gentle agitation for 1 hour our at 
RT. The last washing step was performed and substrate (NBT-BCIP) was added 
to 10 ml of AP buffer to obtain color development as described above. 
 
2.10. Far Western blots analysis of MG2 and Lactoferrin 
SMSL samples from three subjects were electrophoresed and analyzed 
on Far Western blots to investigate interactions between MG2 and lactoferrin. 
Far Western blots were carried out as above, and the only three differences 
were:  
1. Blots were incubated with 100 g of lactoferrin (Sigma) 
2. Immunodetection was performed using a rabbit polyclonal anti-lactoferrin 
antibody (Sigma) diluted 1:2000 in 1% 5000 in 10 ml of 1% BSA and  
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3. The secondary antibody was a goat anti-rabbit IgG conjugated to AP 
(Jackson Immuno Research Laboratories) diluted 1:5000 in 10 ml of 1% BSA. 
 
2.11. Coomassie Blue stained gels of cells panned with MG2 
The solutions used are given below or were described above: 
 
Coomassie Blue Staining Solution  
- 0.25 g Coomassie Brilliant Blue R250 
- 450 ml Deionized water 
- 450 ml Methanol 
- 100 ml Glacial acetic acid 
 
Coomassie Blue Destain Solution 
- 500 ml Deionized water 
- 400 ml Methanol 
- 100 ml Glacial acetic acid 
 
Cell lysates from the Flitrx peptide library that had been panned with MG2 
for 12 days were screened on SDS-PAGE gels prepared as described above to 
confirm the expression of the 63 kDa flagellin-thioredoxin-dodecapeptide fusion 
protein. Proteins on gels were stained for 2 hours with a solution of 0.25% 
Coomassie Brilliant Blue R250 (Sigma) in 45% methanol, 9.0% acetic acid. Gels 
were destained with several changes of 40% methanol containing 10 % acetic 
acid to remove background color.  
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2.12. Sequence analysis of positive anti-IL8, sIgA and MG2 clones. PCR, TA 
Cloning, Transformation and DNA isolation of cells panned with anti-IL8, 
sIgA and MG2 
 
The solutions, culture medium and plates used are given below or were 
described above. 
 
50 X TAE Buffer (2 M Tris acetate and 100 mM EDTA, pH 8.5) 
- 242 g Tris base 
- 57.1 ml Glacial acetic acid 
- 37.2 g Na2EDTA-2H2O 
- Deionized water to 1000 ml 
 
LB medium 
-10 g NaCl 
-10 g Tryptone 
- 5 g Yeast extract  
- Dissolve in 900 ml of Deionized water 
- Adjust pH to 7.0 with 1 N NaOH 
- Deionized water to 1000 ml 
- Autoclave (20 min; liquid cycle) 
 
LB-Ampicilin plates 
- As above plus 15 g Agar 
- Cool down to ~ 50oC 
-1 ml 100 mg/ml Ampicillin 
- Mix and pour plates (store in the dark at 4oC) 
  
Colonies obtained from RMG plates that were investigated on Western 
blots, Far Western blots and on Coomassie blue stained gels were selected for 
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TA cloning and DNA sequence analysis. All PCR and TA cloning products were 
purchased from Invitrogen. PCR reactions were prepared with 38.5 l of H2O, 5 
l of 10 X PCR buffer (100 mM Tris-HCl, pH 8.3, 500 mM KCl, 25 mM MgCl2 and 
0.01% gelatin) 3 l of MgCl2 (50 mM), 1 l of 10 pmol pFlitrx forward primer (5’ -
ATTCACCTGACTGACGAC- 3’), 1 l of 10 pmol pFlitrx reverse primer (5’ -
CCCTGATATTCGTCAGCG- 3’), 1 l of 100 mM dNTPs and 0.5 l of Taq 
Polymerase (5 unit/l). The template consisted of whole cells from selected 
colonies that were toothpicked from MG plates and introduced into the PCR 
reaction mix. PCR was carried out using a PTC-100 Programmable Thermal 
Controller (MJ Research, Watertown, MA). PCR parameters were 94oC for 3 min, 
35 cycles of 94oC for 50 sec, 55oC for 50 sec, 72oC for 90 sec, extension at 72oC 
for 10 min and holding at 4oC. PCR products were examined on 1.5% agarose 
TAE (40 mM Tris acetate containing 2 mM EDTA) gels containing 0.5 μg/ml 
ethidium bromide in order to verify that cells contain the 177 base pair band 
comprising the 36 bases coding for dodecapeptides and thioredoxin flanking 
regions. TA cloning reactions were prepared with 2.0 l of fresh PCR product, 1 
l of 1.2 M NaCl containing 60mM MgCl2 (salt solution), 2 l of H2O and 1.0 l of 
TOPO vector (TOPO TA Cloning Kit, pCR 2.1-TOPO Vector, Invitrogen). The 
ligation reaction was incubated for 5 minutes as in the manufacturer’s 
instructions, and the resulting plasmid was used to transform E. coli JM 109 cells 
(Promega) streaked on LB plates and white/blue screen selected. Selected 
colonies were grown on LB medium and plasmid DNA was extracted using a 
Wizard Plus Miniprep DNA Purification System (Promega) according to 
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manufacturer’s instructions and used for DNA sequence analysis (Genetics Core, 
BUMC). 
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Results 
 
1. Characterization of the cysteine residues in MG2  
 
1.1. Structural organization of MG2 
Secreted MG2 contains 357 amino acids organized into 5 major domains.  
Domain 1 and 2 are located in the N-terminal region. Domain 1 contains 50 
amino acid residues and is the location of the only two cysteines (Cys45 and 
Cys50) in the polypeptide backbone of the apomucin. This domain is followed by 
a moderately glycosylated region (domain 2), a heavily glycosylated region 
(domain 3) comprised of five or six tandem repeats (23 amino acid residues 
each), a second heavily glycosylated region (domain 4) and a small C-terminal 
region (domain 5). The rationale for the present study was that if Cys45 and Cys50 
exist in the dithiol form it should be possible to alkylate these residues directly 
without prior reduction whereas if these residues participate in an intra-molecular 
disulfide bond, reduction would be necessary in order to alkylate the cysteines. 
The structural organization and the cysteines in the two possible configurations 
(dithiol and disulfide form) are shown in Figure 7.  
 
1.2. Electrophoretic analysis 
In view of the recent report that MG2 has the capacity to form dimers and 
tetramers (Mehotra et al., 1998), we first examined the possibility that   
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Figure 7. Diagram showing the structural organization of human salivary 
mucin MG2 
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Figure 7. Diagram showing the structural organization of human salivary 
mucin MG2 
The upper box indicates the primary structure of secreted MG2 that is comprised 
of 357 amino acids organized into regions 1-5 containing 51, 93, 139, 42 and 22 
amino acids, respectively. The middle box shows a portion of region 1 with the 
sequence surrounding the two cysteine residues (underlined) and the bottom box 
indicates the two possible forms in which these residues could exist in the native 
mucin molecule. Abbreviations: Y, tyrosine; K, lysine; C, cysteine; L, leucine; H, 
histidine; R, arginine; P, proline. 
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intermolecular disulfide bonds can occur between MG2 monomers. SDS-PAGE 
was performed using purified MG2 and SMSL with samples electrophoresed  
under both reducing and non-reducing conditions. There was no significant 
difference in the apparent molecular weight of either purified MG2 or MG2 in 
HSMSL under reducing and non-reducing conditions on silver stained gels or on 
Western blots probed with an anti-MG2 antibody (Figure 8A). These results 
provide circumstantial evidence that cysteines in MG2 do not participate in inter-
molecular disulfide bonds.  
Our rabbit polyclonal anti-MG2 peptide antibody is directed against a 
peptide corresponding to residues 47-63 (including Cys50) in the primary 
sequence of MG2. Western blotting experiments were carried out to determine if 
reduction and alkylation or alkylation alone altered the immunochemical 
properties of the apomucin. When blots of native MG2, RA-MG2 or A-MG2 were 
probed with this antibody, comparable immunoreactivity was observed (Figure 
8B). These results show that covalent modification had little effect on the 
immunochemical properties of the apomucin and that this antibody would be 
suitable to detect RA- or A-MG2 in column fractions. 
 
1.3. Chromatography of MG2 on Superose 6 
When MG2 was reduced and alkylated with radiolabeled iodoacetamide 
and chromatographed on a Superose 6 column, the elution profile of radioactivity 
and MG2 immunoreactivity were nearly identical (Figure 9A). The results were  
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Figure 8. Electrophoretic analyses of MG2 
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Figure 8. Electrophoretic analyses of MG2 
A) Mobility of purified MG2 (lanes 1, 3, 5, 7) or MG2 in SMSL (lanes 2, 4, 6, 8) 
under reducing (R; lane 1, 2, 5, 6) and non-reducing (N; lane 3, 4, 7, 8) 
conditions. MG2 detection in gels was achieved by staining with silver (lane 1-4) 
or immuno-detection on Western blots (WB) with anti-MG2 antibody (lane 5-8).  
B) Western blot of purified MG2 (lane 1), RA-MG2 (lane 2) and A-MG2 (lane 3) 
probed with our anti-MG2 antibody. 
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Figure 9. Chromatography of covalently modified MG2 on Superose 6 
A) Elution profile of radioactivity (line with squares) and anti-MG2 
immunoreactivity (line with triangles) of RA-MG2. 
B) Elution profile of radioactivity (line with squares) and anti-MG2 
immunoreactivity (line with triangles) of A-MG2.  
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essentially the same when alkylation was carried out without prior reduction 
(Figure 9B). It is interesting to note that the quantity of 14C-iodoacetamide  
incorporated into either RA-MG2 or A-MG2 was nearly identical and these results 
indicate that both of the cysteine residues occur in the dithiol form. 
 
1.4. RP-HPLC identification of peptides containing cysteine 
The primary sequence of MG2 was examined in the PROWL data base 
(ProteoMetrics, New York, NY) in order to identify enzymatic cleavages that 
would yield cysteine-containing peptides amenable to analysis by mass 
spectrometry. Analysis of theoretical digests of MG2 apomucin showed that a 
number of commonly used enzymes generated either a large number of small 
peptides or a small number of large peptides. Endoproteinase Lys-C was 
selected because the complete theoretical digest obtained with this enzyme 
would yield two peptides with masses amenable to mass spectrometry and each 
peptide would contain one of the two cysteines.    
Therefore, MG2 (50 μg) was alkylated with 14C-iodoacetamide, digested 
with Endoproteinase Lys-C and the digest was chromatographed on a C18 
column developed with an acetonitrile gradient. A partial elution profile of the 
digest is shown in Figure 10. The A229 profile revealed a number of peaks 
indicating that enzymatic fragmentation had occurred. Radioactivity was found 
only in fractions 8 and 9 and the A229 absorbing material in these fractions was 
consistent with the presence of several peptides (Figure 10).  
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Figure 10 
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Figure 10. Partial elution profile of Endoproteinase Lys-C peptides of A-
MG2  
The solid line shows the elution profile of A229 absorbing material and the line 
with triangles shows the elution position of radioactivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82 
 
1.5. Mass spectrometry 
A complete Endoproteinase Lys-C digest of A-MG2 would predict two 
peptides with the sequence Cys-Leu-His-Lys- (peptide 1) and Arg-Cys-Arg-Pro-
Lys- (peptide 2) each containing an alkylated cysteine (Table 2). MALDI-TOF  
mass spectrometry showed that both fraction 8 and 9 contained two peptides 
with M2H+ masses that were identical within less than one mass unit to the 
predicted masses of peptide 1 and peptide 2. 
 
2. Investigation of heterotypic complexes of SIgA and MG2 by peptide 
library 
 
2.1. Anti-IL8 antibody target protein 
The sequence His-Pro-Lys-Phe- corresponds to residues 18-21 of IL8 and 
a monoclonal anti-IL8 antibody has been described to recognize this epitope (Lu 
et al., 1995). Therefore studies were carried out using the anti-IL8 monoclonal 
antibody as a positive control target protein to assess the suitability of the 
panning procedure with a commercially available peptide display library. The 
Flitrx random peptide library was panned for 12 days with the anti-IL8 antibody. 
When libraries from different days of panning were examined on Western blots 
probed with the anti-IL8 antibody, there was a progressive increase in the 
intensity of the immunoreactive 63 kDa fusion protein containing dodecapeptides 
that reacted with this antibody (Figure 11A).  When individual colonies from the 
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Amino Acid Sequence 
 
 
Predicted 
M2H+ 
Observed 
  
C*LHK 
 
279.15 279.10 
RC*PK 
 
358.70 359.10 
 
*Cysteines have 57 additional mass units when derivatized with iodoacetamide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Mass spectral analysis of Endoproteinase Lys-C peptides from alkylated MG2 
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Figure 11. Anti-IL8 Western blots 
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Figure 11. Anti-IL8 Western blots 
Western blots of libraries from different days and isolated colonies from day 12 
were probed with the anti-IL8 antibody. (A) Lanes 1-9 contain libraries from day 
1-12 as labeled. (B) Lanes 1-9 contain isolated colonies from day 12. Both 
Western blots show an immunoreactive 63 kDa band corresponding to the fusion 
protein. 
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library obtained after panning for 12 days were examined on Western blots 
probed with the anti-IL8 antibody, all colonies contained a 63 kDa 
immunoreactive band (Figure 11B). This suggests that the panning procedure 
selects for cells expressing dodecapeptides that should contain the epitope (i.e., 
His-Pro-Lys-Phe-) recognized by the anti-IL8 monoclonal antibody. 
 
2.2. Confirmation that immunoreactive colonies express the anti-IL8 
epitope 
Plasmid DNA isolated from 5 immunoreactive anti-IL8 colonies were 
sequenced using pFlitrx forward and reverse primers. The deduced amino acid 
sequence of dodecapeptides from these 5 clones is shown on Table 3. Three of 
these colonies contained the tetrapeptide sequence His-Pro-Lys-Phe-, which is 
an exact match to the anti-IL8 epitope. The dodecapeptides from two of these 
colonies contained the tetrapeptide sequence, His-Arg-Lys-Phe-, where proline 
at residue 2 was substituted by arginine. This substitution was also observed in 
another study and indicates that some amino acid positions are more conserved 
than others for the antigen-antibody interaction (Lu et al., 1995). In summary, 
dodecapeptides expressing the IL-8 epitope were selected, demonstrating that 
the expected protein-protein interactions occurred and showing the suitability of 
the pFlitrx library for investigating interactions with other target proteins.   
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Table 3. Anti-IL8 selected dodecapeptides 
    V R D D L H P K F W M Q 
          P T H P K F H R A Q G M 
L C G H E T I H P K F L 
      N W K N H R K F P A E R  
      A A R R H R K F V S D P 
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2.2. Dodecapeptides from the initial library 
Panning procedures were performed with two other target proteins,SIgA 
and MG2. Previous studies using peptide display technologies have shown that  
results can identify very specific ligands but also peptide sequences from a large 
number of different apparently unrelated proteins that potentially interact with a 
target protein (Koivunen et al., 1994; Dintilhac and Bernues, 2001). Since we did 
not know in advance the outcome with SIgA and MG2, we decided to calculate 
the frequency of each amino acid in dodecapeptides in the initial Flitrx library in 
order to be able to compare them with ones encountered after panning with 
target proteins. 
When the commercially obtained random peptide display library was 
constructed, a bias was introduced into the 36 base oligonucleotide encoding the 
random dodecapeptides. The sequence of this oligonucleotide used was 
5’(XNN)12 where X is G:A:C:T in the ratio of 7:7:7:3, respectively, and N is any 
nucleotide. This means that at the first base, G, A or C will occur at a frequency 
of 29.16% (7/24) and T will occur at a frequency of 12.5% (3/24) while at the 
second and third bases G, A, C or T will occur at a frequency of 25% each. 
Therefore, the number of codons having T at the first position is reduced and the 
number of codons having G, A or C at the first position is increased. 
For example, the frequency of any codon (i.e., each codon has 3 bases) if 
no bias was introduced is 1.56% (¼ x ¼ x ¼ = 0.0156) but with the T bias the 
frequency of the codons with T as the first base is reduced to 0.78% (3/24 x ¼ x 
¼ = 0.0078) and the frequency of codons with G, A, or C at the first base is 
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increased to 1.82% (7/24 x ¼ x ¼ = 0.018). Consequently, the abundance of Trp, 
Cys, Leu, Phe, Ser and Tyr, all of which have codons with T at the first position, 
is decreased whereas the abundance of all other amino acids is increased. 
Based on the foregoing, the predicted frequency of amino acids in 
dodecapeptides in the initial Flitrx library resulting from the T bias is shown in 
Figure 12.  
 
2.3. SIgA Far Western blots 
 Colonies selected by panning with SIgA were examined on Far Western 
blots. Blots were incubated with SIgA and probed with an anti-SIgA antibody. 
Blots of libraries from different days showed that the immunoreactivity of the 63 
kDa fusion protein increased as the days of panning increased (Figure 13A). 
When 7 individual colonies from the library obtained after panning for 12 days 
with SIgA were examined, 6 colonies had a 63 kDa fusion protein containing 
dodecapeptides that were recognized by SIgA on Far Western blots (Figure 
13B).  These results were similar to those obtained with the anti-IL8 positive 
control, suggesting that the dodecapeptides expressed by the selected E. coli 
cells should contain amino acid sequences that interact with this salivary protein. 
 
2.4. Sequences of SIgA selected dodecapeptides 
Plasmid DNA isolated from 15 immunoreactive SIgA colonies was 
sequenced and the deduced amino acid sequences of the obtained 
dodecapeptides are shown in Table 4. An initial visual inspection did not reveal a  
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Figure 12. Amino acid frequency of dodecapeptides on the initial random 
library 
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Figure 12. Amino acid frequency of dodecapeptides on the initial random 
library 
Expected percentage of each amino acid on the initial random display library 
based on the bias introduced in 36 base oligonucleotide encoding 
dodecapeptides. Tryptophan, is the least abundant amino acid (0.78% of the total 
amino acids) and arginine is the most abundant amino acid (10.93% of the total 
amino acids). 
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Figure 13. SIgA Far Western blots 
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Figure 13. SIgA Far Western blots  
Far Western blots of libraries from different days and isolated colonies from day 
12 were exposed to SIgA and probed with a anti-SIgA α chain antibody. (A) 
Lanes 1-7 contains libraries from day 2-12 as labeled. (B) Lanes 1-7 contain 
isolated colonies from day 12. Both Far Western blots show an immunoreactive 
63 kDa band corresponding to the fusion protein containing dodecapeptides that 
interacted with SIgA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1. E M G G Y N G A L G L A 
   2. D G I M A H G K W D G D 
   3. G W G G V P T G V A T E 
   4. E G I S E S H V Y D T G 
   5. E P G W N P V P L D V I 
   6. L R I V V S K R I M G V 
   7. V V D R P R V E D V R G 
   8. V V D R P T P G D L D A 
   9. V V D R P R V E D V R G 
 10. G G R E P L T V Y G Q S 
 11. M K R R V V R G V V I E 
 12. N K G V G C S M A R G W 
 13. G S M P G Y A S V V S P 
 14. G G P T G R A E Q H V I 
 15. E F G T R W L Y V G V P 
 
Table 4. SigA selected dodecapeptides 
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consensus sequence. Therefore, a further analysis of these 15 dodecapeptides 
was carried out as described below. 
 
2.5. Amino acid frequency of dodecapeptides selected by SIgA 
The frequency of each amino acid in the sublibrary comprising 15 
dodecapeptides resulting from panning with SIgA for 12 days is shown in Figure 
14. Glycine and proline were the most abundant amino acids and cysteine and 
phenylalanine were the least abundant amino acids and the overall amino acid 
composition of this obtained library (SIgA) was notably different from the initial 
library (Figure 12). These results show that SIgA selected for dodecapeptides 
that have specific amino acid compositions.   
 
2.6. SIgA amino acid preference reveals peptides that should interact with 
this salivary protein 
Comparison of the abundance of each amino acid in the dodecapeptides 
obtained after panning with SIgA to those in the initial random peptide library 
revealed that the frequency of 12 amino acids decreased, one amino acid 
(proline) was unchanged and 7 amino acids increased (Figure 15). This result 
suggests that the preferred amino acids may be directly involved in interactions 
with the target protein (SIgA). Inspection of the 15 obtained dodecapeptides 
(Table 4) showed that the enriched amino acids were found adjacent to one 
another in tetra- or pentapeptide sequences in 13 (86.6%) of the 15 
dodecapeptides. A Blast search of the NCBI protein data-base was carried out  
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Figure 14. Amino acid frequency of dodecapeptides selected by SIgA 
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Figure 14. Amino acid frequency of dodecapeptides selected by SIgA 
The percentage of each amino acid present in the library obtained after panning 
with SIgA for 12 days is represented by solid bars. Cysteine and phenylalanine 
were the least abundant amino acids (0.55% each) and glycine was the most 
abundant amino acid (17.77%). 
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Figure 15. Comparison of the abundance of amino acids in dodecapeptides 
selected by SIgA versus those in the initial random library 
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Figure 15. Comparison of the abundance of amino acids in dodecapeptides 
selected by SIgA versus those in the initial random display library 
The solid bars represent the fold increase or decrease in the percentage of each 
amino acid in dodecapeptides in the library obtained after panning for 12 days 
with SIgA. The percentage of glutamine was decreased 3.27 fold and  the 
percentage of tryptophan was increased 3.55 fold compared to dodecapeptides 
in the initial  random display library. 
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with the tetra- or pentapeptide sequences described above in order to identify 
known proteins containing these sequences as possible candidates for 
interaction with SIgA. The sequence Glu-Met-Gly-Gly-Tyr- (Table 4; SIgA, clone 
1) was an identical match to residues 69-73 of the VPU protein from Human 
Immunodeficiency Virus type 1 (Peeters et al., 1999). The sequence Trp-Asp-
Gly-Asp- (Table 4; SIgA, clone 2) occurs at residue 506-509 of the 
ferripyoverdine receptor on the outer membrane of P. aeruginosa (Poole et al., 
1993). The sequence Gly-Trp-Gly-Gly-Val- (Table 4; SIgA, clone 3) is identical to 
residues 358-362 of pyrogenic exotoxin B from Streptococcus pyrogenes (Kapur 
et al., 1993). Interactions between SIgA and these viral and bacterial proteins, if 
they do indeed occur in vivo, could be important in maintenance of homeostasis.  
 
2.7. Coomassie blue stained gels of MG2 selected cells 
Isolated colonies selected by panning with MG2 for 12 days were 
examined on SDS-PAGE gels stained with Coomassie blue to confirm the 
expression of the 63 kDa fusion protein (Figure 16). All colonies contained the 63 
kDa band and, based on the positive epitope identification obtained with the anti-
IL8 control, the dodecapeptides expressed by the E. coli cells selected by MG2, 
should contain amino acid sequences that interact with this salivary mucin. 
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Figure 16. Coomassie blue stained gels of isolated colonies interacting 
with MG2 
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Figure 16. Coomassie blue stained gels of isolated colonies interacting 
with MG2 
Lanes 1-9 show the 63 kDa fusion protein from 9 different colonies of the library 
obtained after panning with MG2 for 12 days. 
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2.8. Sequences of MG2 selected dodecapeptides 
Plasmid DNA isolated from 20 colonies selected by panning for 12 days 
with MG2 was sequenced and the deduced amino acid sequences of the 
dodecapeptides are shown in Table 5. Analyses of the dodecapeptides did not  
immediately reveal an obvious consensus sequence. Therefore, a further 
analysis of these 20 dodecapeptides was carried out as described below. 
 
2.9. Amino acid frequency of dodecapeptides selected by MG2 
The frequency of each amino acid in the sublibrary comprising 20 
dodecapeptides resulting from panning with MG2 for 12 days is shown in Figure 
16. Arginine was the most abundant amino acid and asparagine was the least 
abundant amino acid. Comparison of the amino acid frequency in the initial 
library (Figure 12), the one obtained after panning with SIgA (Figure 14) and the 
one obtained after panning with MG2 (Figure 17) reveals that they are notably 
different. These results, together with the data obtained with the anti-IL8 antibody 
positive control provide strong evidence that the panning procedure selects for 
Flitrx dodecapeptides that exhibit protein-protein interactions with each specific 
target proteins.  
 
2.10. A putative motif in MG2 selected dodecapeptides  
Comparison of the abundance of each amino acid in dodecapeptides after 
panning with MG2 for 12 days to those in the initial random peptide library 
showed that the frequency of 7 amino acids decreased, 3 were essentially  
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  1. Q C H Y L A L L L D N L 
  2. Q C H Y L A L L L D N L 
  3. H P L R L A A L P K N K   
  4. T K V Q G P I G S R R R 
  5. A S P P A V W K A V W L 
  6. I G L P W V I R G S L K 
  7. A A H A L L C T G N L S 
  8. C A L L R W A S S M V A 
  9. V I V H T G A Y T R L R 
10. V A I R W L S G V P R V 
11. R I Y A I P F Y H R R S 
12. F A A I L S L I Y S V E 
13. L W L A H R Q C C L Q P 
14. C R L A T M P L H I K M 
15. Y V V W I R V K R A R S 
16. G L R R S V F R R K G D 
17. K S D Q M R L R V R S V 
18. P M H T S L S I F L R L 
19. S A R W C T R G S V G R 
20. G I W V Y G L G M V V R 
Table 5. MG2 selected dodecapeptides 
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Figure 17. Amino acid frequency of dodecapeptides selected by MG2 
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Figure 17. Amino acid frequency of dodecapeptides selected by MG2 
The percentage of each amino acid present in the library obtained after panning 
with MG2 for 12 days is represented by solid bars. Asparagine was the least 
abundant amino acid (1.51%) and arginine was the most abundant amino acid 
(14.40%). 
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unchanged and 10 amino acids increased to varying degrees (Figure 18). In 
addition, a motif containing 3 or more consecutive amino acids with aliphatic side 
chains was present in clone 1-13 (Figure 19). Inspection of the amino acid 
sequences of these motifs (Table 5; clones 1-13) shows that the sequence X-
Ala-Leu-Leu-Z-, encountered 5 times, was the most abundant consensus 
sequence. A search of our salivary protein data base with the motif X-Ala-Leu-
Leu-Z where X is His, Leu or Cys and Z is Cys, Leu, Pro or Arg was performed 
and revealed that lactoferrin was the only major salivary protein containing a 
tetrapeptide match. The sequence Ala-Leu-Leu-Cys- encountered in one of our 
clones (Table 5; clone 4) occurs at residues 147-150 of lactoferrin.  
 
2.11. Heterotypic complex between MG2 and Lactoferrin 
Far Western blotting experiments were conducted in order to verify if MG2 
and lactoferrin are able to form a heterotypic complex. HSMSL was examined by 
SDS-PAGE on 7.5% gels and proteins were transferred to nitrocellulose 
membranes. When blots were probed with anti-MG2 antibodies, a 180 kDa 
immunoreactive band was observed (Figure 20A; Western blot) and when blots 
were probed with anti-lactoferrin antibodies an 80 kDa immunoreactive band was 
observed (Figure 20B; Western blot). These results show that the primary 
antibodies against MG2 and lactoferrin react with their corresponding antigens in 
HSMSL. When blots were first incubated with lactoferrin and subsequently 
probed with anti-lactoferrin antibodies, a strong 180 kDa immunoreactive band 
coincident with the electrophoretic mobility of MG2 was observed 
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Figure 18. Comparison of the abundance of amino acids in dodecapeptides 
selected by MG2 versus those in the initial library 
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Figure 18. Comparison of the abundance of amino acids in dodecapeptides 
selected by MG2 versus those in the initial random display library 
The solid bars represent the fold increase or decrease in the percentage of each 
amino acid in dodecapeptides in the library obtained after panning for 12 days 
with MG2. The percentage of threonine was decreased 2.75  fold and  the 
percentage of tryptophan was increased 4.85 fold compared to dodecapeptides 
in the initial  random display library. 
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Figure 19. Observed motif on dodecapeptides interacting with MG2 
 
 
 
 
 
 
 
 
 
 
 ou □ D00000oo0 
ov □ D00000oo0 
□00 □00000 □ 0 □ 
D □ 0o0000D □□□ 
0v0000D □ 00D0 
D0000v00Dv0o 
0000D00D0v0D 
00o000vv0o0v 
v000 □ Dovvv00 
000 □ D0v000 □ 0 
000 □ v00Du □0 □ 
00D0D000v00 □ 
□ 0D000DD □□ Dv 
 111 
Figure 19. Observed motif on dodecapeptides interacting with MG2 
A motif (filled circles) of at least three consecutives amino acids containing 
aliphatic side chains was observed in 65 % of the dodecapetides obtained with 
MG2 target protein.  Gly, Ala, Val, Leu, Ile and Pro are represented by circles. 
Ser, Cys, Thr and Met by trapezoid. His, Lys and Arg by squares. Phe, Tyr and 
Trp are represented by triangles. Asp, Glu, Asn and Gln are represented by 
pentagons.     
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Figure 20. Interaction between MG2 and Lactoferrin 
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Figure 20. Interaction between MG2 and Lactoferrin 
SMSL (50μl) from two subjects were electrophoresed on SDS-PAGE 
polyacrilamide gels and transferred to membranes. Immunoreactive bands 
corresponding to MG2 and lactoferrin can be observed on:  
A) Anti-MG2 Western blot 
B) Anti-Lactoferrin Western blot 
C) Anti-Lactoferrin Far Western blot  
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was observed (Figure 20C; Far Western blot). In addition, a smaller 80 kDa 
immunoreactive band was present corresponding the lactoferrin also present in 
HSMSL. This demonstrates that MG2 and lactoferrin form a heterotypic complex 
in a solid phase assay (i.e., Far Western blot). This result is consistent with the 
selection of the sequence Ala-Leu-Leu-Cys- by peptide display technology that 
allows identification of lactoferrin as a candidate to interact with salivary mucin 
MG2. 
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Discussion 
 
1. Characterization of the cysteine residues in MG2 
To date thirteen distinct mucin genes have been isolated and are named 
MUC1-MUC4, MUC5AC, MUC5B, MUC6-8, MUC11-13, and MUC16 in order of 
their discovery (for review, Offner and Troxler, 2000). As more structural 
information has become available it has been recognized that human mucin 
genes can be separated into 3 distinct classes: large gel forming mucins (MUC2, 
MUC5AC, MUC5B, MUC6), large membrane associated mucins (MUC1, MUC3, 
MUC4, MUC12-13) and the small soluble mucin represented by MUC7 (i.e., 
MG2). Insufficient information is available to assign MUC 8, MUC11 and MUC16 
to one of these categories. 
Large gel-forming mucins have molecular weights of 20-40 million daltons 
and are comprised of monomers (1-2 million daltons) linked together by disulfide 
bonds. They are synthesized in polyribosomes bound to the endoplasmic 
reticulum (ER). Upon translocation to the ER, the apomucin molecule folds and 
dimerization occurs through interchain disulfide bonds between cysteine residues 
in the C-terminal region. Mucin dimers are N-glycosylated in the ER and 
transported to the Golgi where O-glycosylation and multimerization occurs 
through interchain disulfide bonds involving cysteine residues in the N-terminal 
region (Perez-Villar and Hill, 1999). Large membrane-associated mucins are 
monomeric, contain few to many cysteine residues and, in some cases, are 
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cleaved during secretion into two subunits which form a heterodimeric complex at 
the cell surface (Carraway et al., 2000).  
MG2 is the product of the MUC7 gene and is a very atypical mucin due to 
its small size, small number of tandem repeats and glycan composition. MUC7 
expression is limited to submandibular/sublingual glands (Bobek et al., 1993), 
minor salivary glands (Bolscher et al., 1999), trachea (Biesbrock et al., 1997) and 
submucosal glands in human bronchial tissue (Sharma et al., 1998). Despite a 
considerable body of information indicating that MG2 in salivary secretions and 
whole saliva exists as a monomer, a recent report has suggested that MG2 can 
form dimers and tetramers in vitro (Mehotra et al., 1998). Since the present work 
showed that MG2 had the same electrophoretic mobility under both reducing and 
non-reducing conditions it seems likely that the formation of dimers and 
tetramers involves hydrophobic and electrostatic interactions and does not 
involve disulfide linkages between cysteine residues. 
Several studies have reported that oral microbes interact with specific 
domains in salivary proteins. Interactions are frequently determined by specific 
protein-protein and/or lectin-carbohydrate recognition, and they help to stabilize 
complementary domains in surfaces that bacterial proteins have evolved to 
recognize and bind (Ellen et al., 1997). Acidic proline-rich protein (PRP) and 
statherin that had been immobilized onto nitrocellulose membranes or 
hydroxyapatite beads were reported to bind to P. gingivalis. Protein-protein 
interactions through domains of the P. gingivalis fimbriae, mediate the bacterial 
adhesion to these salivary proteins. The sequence Pro-Gln-Gly-Pro-Pro-Gln- on 
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PRP1 was specifically described to be part of the motif recognized by 
P. gingivalis (Amano et al., 1998). A receptor for salivary agglutinin, a mucin like 
glycoprotein, on S. mutans was reported to mediate the adherence of S. mutans 
to S. sanguis or A. viscosus (Lamont et al., 1991).  Interactions of S. gordonii, S. 
sanguis and S. oralis with MG2, highly glycosylated proline-rich glycoproteins, 
and alpha-amylase, suggested that some oral streptococci could bind specifically 
to these salivary glycoproteins (Murray et al., 1992). Salivary alpha-amylase was 
described to interact with S. gordonii and may serve as a receptor for amylase-
binding streptococci in the acquired enamel pellicle (Scannapieco et al., 1995).  
Salivary mucin MG2 interacts with a diverse number of oral microbes 
(Reddy et al., 1993; Groenink et al., 1996, Liu et al., 1999, 2000, 2002) and the 
existence of a bacterial aggregating epitope on this salivary mucin has been also 
reported (Piotrowski et al., 1992). A previous study reported that reduction and 
alkylation nearly abolished the ability of MG2, and a recombinant fragment of 
MG2 comprising the N-terminal 144 residues (rNMUC7), to bind to S. mutans 
(Liu et al., 1999, 2000). Based on these results it was postulated that the 
cysteines in both MG2 and rNMUC7 are contained in a structural motif necessary 
for bacterial binding. 
Several studies described that reduced cysteines (dithiol) are involved in 
receptor-ligand interactions. Steroid binding to hepatoma tissue culture cell 
glucocorticoid receptors involves at least two sulfhydryl groups and formation of 
an intramolecular disulfide bond prevented steroid binding (Miller and Simons, 
1988). Biochemical analyses with covalent affinity labels and thiol-blocking 
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reagents suggested possible roles for cysteine residues in binding of steroid to 
the amino acid hormone-binding domain at the C-terminal end of mammalian 
glucocorticoid receptors, and mutations in cysteine 671 and cysteine 742 caused 
substantial reductions in steroid binding (Chen and Stallcup, 1994). Another 
study also report that two cysteine residues in the hormone-binding domain of 
human glucocorticoid receptor determine glucocorticoid binding specificity (Yu et 
al., 1995). 
Therefore, it was of interest to determine whether cysteine 45 and 
cysteine 50 in the bacterial binding motif occurring in MG2 exist in the dithiol or 
disulfide form. The present work showed that these cysteines could be alkylated 
directly without prior reduction and that peptide 1 (Cys-Leu-His-Lys-) and peptide 
2 (Arg-Cys-Arg-Pro-Lys-) were identified in the endoproteinase Lys-C digest of A-
MG2. These results show that in the structural motif of MG2 required for binding 
to bacteria, the cysteines occur in the dithiol form. Characterization of the 
physical state of the cysteine residues in this structural motif of MG2 should 
provide insights into mucin interactions with oral microbes, with other salivary 
proteins and with both hard and soft tissues in the oral cavity. For example, it 
would be of interest to generate recombinant MG2 molecules lacking one or both 
cysteines and to assess the properties these molecules in binding assays. Such 
studies could be useful for identification of receptors on bacterial surfaces that 
interact with MG2. Peptides with sequences surrounding the cysteines are 
potential candidates for therapeutic use as co-adjuvants for modification of 
microbial interactions with oral surfaces.  
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2. Investigation of heterotypic complexes of SIgA and MG2 by peptide 
display  
Functional proteomics, the comprehensive analysis of proteins with 
special attention to their functions, investigates how protein-protein interactions 
control transcription, cell division, cell proliferation, mediate signal transduction, 
oncogenic transformation, and regulation of cell death (Luker et al., 2002).  
Proteins networks participate in growth, reproduction, and in the interaction 
between cells, integrating different systems and maintaining homeostasis. 
Different methods have been used to identify and analyze protein-protein 
interactions and some will be breathily discussed bellow. Two-hybrid systems, an 
in vivo yeast genetic screening method, have been used to the identify protein-
protein interactions since its development (Fields and Song, 1989). A target 
protein, generally called the bait, is expressed in yeast as a fusion to the DNA-
binding domain of a transcription factor lacking a transcription activation domain. 
To identify proteins that interact with the bait, a plasmid library that expresses 
cDNA-encoded proteins fused to a transcription activation domain is introduced 
into the yeast. Interaction of a cDNA-encoded protein with the bait will activate a 
reporter gene, allowing cells containing the interactive proteins to be identified. 
Protein microarray is a technology that allows analysis of several protein-
protein interactions within a single experiment. This technique can be used to 
reveal unknown enzyme-substrate and DNA-protein interactions. Basically, 
microspots of capture molecules are immobilized onto a solid support and 
exposed to samples containing binding molecules candidates. Detection of 
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complex formation within each microspot can be verified using reading systems 
based on fluorescence, chemiluminescence, mass spectrometry, radioactivity 
and others (Templin et al., 2002). 
Immunoaffinity chromatography utilizes biospecific recognition of antigenic 
epitopes by antibodies and can be used to examine enzyme-enzyme, subunit-
oligomer, protein-antibody, protein-chaperone and other protein-protein 
interactions. 
Mixtures of proteins identified as stained bands in polyacrylamide gels can 
be subjected to in situ digestion with proteases, and extracted peptide fragments 
can be analyzed by Mass Spectrometry (MS). Genomic and protein information 
databases can than be used to analyse MS results and identify the components 
of the protein complex.  
Random peptide display is an important biomolecular display technology 
to identify protein-protein interactions (Smith, 1985). This broadly applicable 
method can be used to identify homo- or heterotypic complexes. A library can be 
made by cloning degenerate oligonucleotides encoding random peptide 
sequences into a vector.  Peptides will be expressed on the surface of a phage 
or bacteria and panning the library with the protein of interest results in selection 
of specific clones. Sequence analysis of obtained clones provides the peptide 
sequence that participated in the protein-protein interaction with the target 
protein. This technique is currently used in microbiology, biotechnology and 
virology and was selected to be used in the present study.  
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Several studies have reported the occurrence of complexes in saliva. 
Interactions between salivary proteins are an important property of these 
macromolecules and modulate a number of processes including establishment of 
the enamel pellicle on tooth surfaces (Rykke et al., 1990; Yao et al., 2001), 
maintenance of the biofilm coating epithelial surfaces in the oral cavity (Collins 
and Dawes, 1987) and colonization of the oral surfaces by microbes (Marcotte 
and Lavoie, 1998).  Salivary mucin MG1 selectively forms heterotypic complexes 
with a number of salivary proteins including amylase, proline-rich proteins, 
statherin, and histatins (Iontcheva et al., 1997). Yeast two-hybrid system 
mapping studies have identified statherin and histatin binding domains in MG1 
(Iontcheva et al, 2000). SIgA have been described to form heterotypic complexes 
with salivary agglutinins, lactoferrin, lactoperoxidase and MG2 (Rundegren and 
Arnold, 1989; Kilian et al., 1988; Tenovuo et al., 1982; Biesbrock et al., 1991). In 
saliva, these complexes may enhance these proteins properties, decrease their 
susceptibility to proteolysis and facilitate their delivery to specific areas in the oral 
cavity. Since SIgA is the major immunoglobulin of the adaptive immune system 
present in saliva and MG2 is also an important component of the innate immune 
system in this fluid, we used a random peptide display library to discover 
previously unrecognized complexes between these molecules and other proteins 
occurring in the oral environment. 
In the present study the anti-IL8 antibody was used as a positive control 
and the results show that the random peptide display library, as it was exposed 
to the anti-IL8 target proteins in consecutive days, was enriched in clones 
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containing the IL8 epitope. Three immunoreactive clones contain tetrapeptide 
sequences with an exact match to the IL-8 epitope and two immunoreactive 
clones contain tetrapeptide sequences with one amino acid mismatch (Table 3). 
These results are in agreement with a previous study with a larger number of 
clones where the second amino acid (i.e., Pro) in the epitope was changed with 
the Pro/Arg substitution (Lu et al., 1995). This scenario led us to initiate the 
panning experiments with SIgA and MG2. 
SIgA was panned with the random library for twelve days. In order to 
evaluate if all selected clones contain dodecapeptides that interact with this 
protein, Far Western blots were conducted and an enrichment of the library in 
immunoreactive clones was observed suggesting that selected cells should 
express dodecapeptides that interact with SIgA. Sequence analyses reveals a 
motif of short peptides (tetra- or penta-peptides) composed of the consecutive 
preferred amino acid that has the potential to interact with SIgA in vivo. 
Encountered motifs sequences were present in the VPU protein, the 
ferripyoverdine receptor and pyrogenic exotoxin B. The VPU protein from Human 
Immunodeficiency Virus type 1 is a component of the viral envelope that homo-
oligomerizes to form a channel for ion flux (Fischer and Sansom, 2002). It is 
interesting in this regard that interactions between SIgA and HIV play an 
important role in the immune system (Skott et al., 1999; Moja et al., 2000; Devito 
et al., 2000) and may neutralize HIV-1 infection at mucosal sites (Matsuda and 
Noda, 2000). The HIV-1 epitopes against which SIgA is directed are not fully 
characterized (Moja et al., 2000), therefore the VPU protein sequence that was 
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observed in this study may, in principle, be used as a candidate in future studies 
to the development of mucosal vaccines against HIV-1. Ferripyoverdine is a 
receptor on the outer membrane of P. aeruginosa (Poole et al., 1993). Binding of 
SIgA to the ferripyoverdin receptor may interfere with uptake of iron and reduce 
the risk of infection by this organism. The pyrogenic exotoxin B from S. 
pyrogenes is a cysteine protease that plays a role in bacterial dissemination, 
colonization, invasion and inhibition of wound healing and also cleaves human 
interleukin 1 (IL1) beta precursor to generate the biologically active form of IL1 
(Kapur et al., 1993). Neutralization of this toxin by SIgA should be beneficial for 
human health. Unfortunately, none of the above proteins could be obtained to 
use different technologies that could confirm the interactions of these proteins 
and SIgA. Nevertheless, the panning procedure and Far Western blots results 
showed that these proteins could in principle interact with SIgA. Again, the 
putative interactions between SIgA and these three proteins points to several 
mechanisms in which SIgA could be involved playing a major role in the adaptive 
immune system.  
MG2 was also panned with the random library for twelve days. In order to 
evaluate if all selected clones contain dodecapeptides that interact with this 
protein, Far Western blots were conducted but no immunosignal of the 63 kDa 
fusion protein was observed. A possible explanation for this observation is that 
previous reports have shown that binding of bacteria occur in a motif present in 
the N-terminal region of MG2 (Liu et al., 1999; 2000), and our antibody is 
directed to amino acids 47-63 localized on the same region. If the 
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dodecapeptides are also interacting with this MG2 motif on blots, we can 
hypothesize that these interactions will alter/block the recognition of the 
polypeptide backbone of the mucin by the anti-MG2 antibody. Nevertheless, the 
expression of the fusion protein was confirmed on Coomassie blue stained gels 
and sequence analysis of dodecapeptides show a motif based on the amino acid 
side chains characteristics and a consensus sequence (Ala-Leu-Leu-) that is 
encountered on salivary lactoferrin. Far Western blots were conducted and the 
results show that MG2 and lactoferrin form a heterotypic complex in vitro. 
Lactoferrin is an iron-binding protein that inhibits growth of bacteria and fungi 
(Weinberg, 1995) and, like MG2, is also considered a component of the innate 
immune system. Formation of a heterotypic complex between these proteins in 
vivo should possibly enhance their antimicrobial properties.   
In lysozyme, the sequence Ser-Ala-Leu-Leu-Gln- occurs on residues 100-
104. This sequence is not flanked by the amino acids that were observed on 
clones obtained after panning with MG2 (i.e. His, Leu or Cys on the N-terminal 
end or Cys, Leu, Pro or Arg on the C-terminal end). Using the Far Western blot 
technology that successfully demonstrated complexing between MG2 and 
lactoferrin, no interaction was detected between MG2 and lysozyme using a 
commercially available rabbit polyclonal antibody against lysozyme 
recommended for probing blots. A possible explanation for this could be that C-
terminal cysteine present in the lactoferrin motif (Ala-Leu-Leu-Cys-) and not 
present at this position in lysozyme (Ala-Leu-Leu-Gln-), may be essential for 
binding to MG2. This hypothesis is also supported by the fact that cysteines, as 
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mentioned in the discussion part 1 (Characterization of the cysteine residues in 
MG2), were reported to be involved in receptor-ligand interactions. It is also 
possible that the Ala-Leu-Leu- (encountered consensus sequence) in lysozyme 
exists in a spatial configuration that prevents interactions between lysozyme and 
MG2. 
In summary, the function of the majority of the proteins is related to their 
ability to interact with other specific molecules. Protein-protein interactions 
maintain homeostasis and salivary proteins interactions are fundamental in oral 
health. To our knowledge this is the first study to use peptide display technology 
using salivary proteins as bait to identify complexing in the oral environment. The 
results from the present study reveal microbial proteins that may interact with 
SIgA and a heterotypic complex between MG2 and lactoferrin that was confirmed 
in a solid phase assay. To this date, complex formation between these two 
salivary proteins was never reported. Since both MG2 and lactoferrin are 
important components of the innate immunity in the oral cavity, this putative 
interaction may enhance the properties of both proteins. Lactoferrin binds ferric 
ions, possesses antibacterial, antimycotic, antiviral, antineoplastic and anti-
inflammatory properties. MG2 interacts with several oral microbes and exhibit 
candidacidal and bactericidal activity. MG2 is present in the biofilm that covers 
mucosal surfaces, has affinity for hydroxyapatite, and was identified in pellicle 
formed on cementum. Complexing between MG2 and lactoferrin may carry 
lactoferrin to the cementum, localizing these antibacterial and anti-inflammatory 
proteins in a site that is constantly challenged by pathogenic species of oral 
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microbes. It is also possible that the high content of carbohydrates in MG2, may 
improve the resistance to proteolytic attack of both proteins participating in this 
heterotypic complex. Complexing may also delay removal of these two proteins 
from the oral cavity, allowing them to exercise their several important functions in 
the oral environment. In conclusion, complexing between salivary components 
should be a useful mechanism to improve oral health, therefore overall health, 
and consequently the quality of life.    
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